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ABSTRACT

PHARMACOLOGICAL CHARACTERIZATION OF NOVEL SEROTONIN
TRANSPORTER INHIBITORS IDENTIFIED THROUGH COMPUTATIONAL
STRUCTURE-BASED VIRTUAL SCREENING

By
Michael J. Wasko
December 2020

Dissertation supervised by Dr. Paula A. Witt-Enderby
Depression is a mental health disorder affecting greater than 350 million people worldwide
with roughly 7% of the United States population diagnosed as of 2017. The selective serotonin
reuptake inhibitors (SSRIs) have been the mainstay of pharmacotherapies for depression for the
last 40 years. The SSRIs target the serotonin transporter (SERT), a monoamine transporter (MAT)
responsible for terminating serotonergic neurotransmission.

The SSRIs are not perfect

therapeutics and suffer from delayed response times, inconsistent efficacy among patients, and
often produce intolerable side effects.

Therefore, a strong need exists to develop new

antidepressants that are more efficacious and have fewer adverse effects. The Surratt and Madura
laboratories approached this problem through the application of computational chemistry and
classical pharmacology to rationally identify novel MAT inhibitors and ligands. The work within
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this doctoral thesis encompasses a structure-based virtual screen targeting SERT and the
pharmacological analysis of the compounds identified from the screen.
Previous virtual screens utilized SERT homology models based on a bacterial leucine
transporter as the structural template (Manepalli et al., 2011; Kortagere et al., 2013; Gabrielsen et
al., 2014; Nolan et al., 2014). More recently, the human SERT crystal structure was published by
the Eric Gouaux laboratory (Coleman et al., 2016) and used as the template for the present study.
The Molecular Operating Environment software was chosen to target the orthosteric binding
pocket S1 due to performance during benchmarking evaluations of the scoring function
parameters. The HitDiscoverer chemical library was screened with the SERT computational
model, and SERT ligand candidates were evaluated by predicted binding affinity, the Lipinski
Rule of 5, and chemical uniqueness.

Nine compounds were purchased and subjected to

pharmacological analysis for binding, inhibition efficacy, and release potential. One compound
bound to SERT with reasonable affinity; two compounds inhibited serotonin transport in in vitro
assays. None of the compounds promoted the release of internal serotonin (i.e., efflux). In
conclusion, computational modeling was successfully used to identify novel inhibitors of the
human SERT in a time and cost-efficient manner demonstrating the applicability to academic
research.
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Chapter 1: Introduction
Depression
Depression is a disorder that affects a person’s mental integrity, resulting in a period of
prolonged sadness that interrupts normal functioning (Akil et al., 2018). It is characterized by a
spectrum of clinical symptoms including anhedonia, depressed mood, sleep imbalances, fatigue,
suicidal tendencies, deflated self-esteem, and sexual dysfunction (Wong and Licinio, 2001; Nestler
et al., 2002). Although depression is widely underdiagnosed, it is estimated that more than 350
million people are diagnosed worldwide (Smith, 2014).

Additionally, depression has been

classified as the leading cause of worldwide disability with over 76.4 million work-years lost per
year (Smith, 2014). The National Institute of Mental Health (NIMH) reported that 7.1% of adults
in the United States, roughly 17.3 million people, experienced a depressive episode of at least two
weeks during 2017 (National Institute of Mental Health). The American Psychiatric Association
further classified individuals that display more than five depressive symptoms per day over two
weeks as having major depressive disorder (MDD) (Hillhouse and Porter, 2015). MDD is typically
seen as an adult-onset disease, and women are 2 - 3 times more likely to be diagnosed with MDD
(Kessler et al., 2012; Hillhouse and Porter, 2015).
The currently available antidepressant medications are not without their limitations.
Alarmingly, a large percentage of MDD patients (34-46%) do not respond to current antidepressant
treatments, a condition classified as treatment resistance (Fava and Davidson, 1996; Hillhouse and
Porter, 2015; Akil et al., 2018). The Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) clinical trial by the NIMH showed that 28% of patients obtained remission of their
depression using citalopram after 14 weeks (Insel and Wang, 2009). Beyond the issue of
effectiveness, this study also highlighted another issue regarding the slow onset of remission from
the symptoms of depression. It is common for antidepressants to have a latency period of weeks
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to months before remission occurs (Insel and Wang, 2009; Scheuing et al., 2015). Regardless of
efficacy, a variety of side effects from the medication can occur including gastrointestinal distress,
headaches, sexual dysfunction, insomnia, weight gain, dry mouth, anxiety, and fatigue (Santarsieri
and Schwartz, 2015; Cartwright et al., 2016). Adherence to prescribed antidepressant treatments
is another problem with some studies reporting around 50% of patients ending treatments
prematurely (Sansone and Sansone, 2012).
Pharmacological Antidepressants Leading to SSRIs:
Monoamine Oxidase Inhibitors (MAOIs)
The identification of modern antidepressants is linked with the development of tuberculosis
treatments during the late 1940s and early 1950s. Isoniazid (isonicotinyl hydrazide) was first
synthesized by Hoffmann - La Roche and proved to be an effective anti-tubercular agent (Figure
1.1) (Hillhouse and Porter, 2015). This led to the synthesis of derivative molecules based on
isoniazid in an attempt to develop active analogs resulting in iproniazid (isopropyl-isonicotinyl
hydrazide; Figure 1.1) (Hillhouse and Porter, 2015). Clinical trials in 1952 at the Sea View
Hospital on Staten Island, NY identified the antidepressant potential of iproniazid and initially
classified CNS activation as a side effect (López-Muñoz and Alamo, 2009). Tuberculosis patients
receiving iproniazid at Sea View were reported to experience strikingly increased energy and
social behavior. Iproniazid was shown by the Ernst Albert Zeller lab in 1952 to be an inhibitor of
the enzyme monoamine oxidase (MAO) that breaks down monoamine neurotransmitters including
serotonin, dopamine, and norepinephrine (Table 1.1) (Zeller et al., 1952; López-Muñoz and
Alamo, 2009).
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Table 1.1: Chemical Structure of the Monoamine Neurotransmitters.

Iproniazid hepatotoxicity led to its withdrawal from the U.S. market, but it was replaced
by more potent MAO inhibitors (MAOIs) including phenelzine, isocarboxazid, and
tranylcypromine (Figure 1.1) (Shulman et al., 2013). MAOIs can be classified by their selectivity
and binding mode to the MAO enzymes (Shulman et al., 2013). Two isoforms of MOA – MAOA
and MAOB – differ based on their substrates; MOAA oxidizes serotonin, while dopamine and
norepinephrine are broken down by both MAOA and MAOB (Youdim et al., 2006). Selective
inhibition of the MAO isoforms can be achieved with low doses of moclobemide (MAOAselective), pargyline (MAOB-selective), or selegiline (MAOB-selective) (Figure 1.1) (Shulman et
al., 2013). Additionally, nonselective MAO inhibitors exist including phenelzine and high doses
of selegiline (Figure 1.1) (Shulman et al., 2013).
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Table 1.2: Chemical Structures of the MAOIs.

Biogenic Amines: Serotonin
The MAOIs modulate the signaling of the biogenic amines including serotonin,
dopamine, and norepinephrine (Figure 1.2) by preventing the destruction of the neurotransmitters,
leading to increased signaling via their respective receptors (Shulman et al., 2013). With respect
to current antidepressant therapies, the serotonergic system plays a greater role than the other
biogenic amines (Yohn et al., 2017).

Serotonin is derived from the essential amino acid

tryptophan, of which approximately 2% in the body is converted into serotonin and enters the CNS
through the L-amino acid transport proteins (Best et al., 2010; Chen and Miller, 2013). Ltryptophan is converted into serotonin by the sequential actions of the aromatic L-amino acid
decarboxylase (AADC) enzyme and the tryptophan hydroxylase 2 (TH2) enzyme, the latter being
the rate limiting step within serotonergic neurons (Lovenberg et al., 1962; Best et al., 2010; Chen
and Miller, 2013). Serotonin is collected and recycled into vesicles within the neuron through the
4

vesicular monoamine transporter 2 (vMAT2) (Kroeze et al., 2012). Once serotonin is released
from the neuron, it binds to and activates one of 14 serotonin receptor types consisting of 13 G
protein-coupled receptors (GPCRs) and one ligand-gated ion channel (Nichols and Nichols, 2008).
The 14 receptors are grouped into 7 families (5HT1-7) based upon the coupling G protein and
genetic similarity; the 5HT3 receptor is the ion channel.
The 5HT1A, 5HT1B, 5HT4, 5HT6 and 5HT7 receptors have been associated with clinical
depression (Yohn et al., 2017). The 5HT1A is both a presynaptic autoreceptor and a postsynaptic
receptor. Presynaptic 5HT1A receptors inhibit firing of serotonergic neurons and are thought to
contribute to the latency period of antidepressant activity, although sustained receptor occupancy
leads to desensitization (Chilmonczyk et al., 2015). The postsynaptic 5HT1A found in the dentate
gyrus has been implicated in adult hippocampal neurogenesis in response to antidepressants
(Samuels et al., 2015). Mice specifically lacking the 5HT1A receptor in the dentate gyrus do not
exhibit neurogenesis from treatment with the antidepressant fluoxetine (Samuels et al., 2015). The
5HT1B receptor is a widely-distributed inhibitory GPCR found on presynaptic neurons (Tiger et
al., 2018). The 5HT1B shares 43% of the amino acid sequence of the 5HT1A and can function as
an autoreceptor that inhibits serotonin release (Tiger et al., 2018). Mice lacking the 5HT1B display
antidepressant- and antianxiety-like properties in rodent models of depression (Tiger et al., 2018).
The 5HT4 has been implicated in both anxiety and depression, with activation of the receptor
producing short-term anxiolytic properties in mice and long-term promotion of adult hippocampal
neurogenesis (Mendez-David et al., 2014). The 5HT6 receptor involvement in depression needs
more study, as both agonists and antagonists of the receptor have been identified to have anxiolytic
and antidepressant-like effects in rodent models (Yohn et al., 2017). The 5HT7 receptors are
expressed in the limbic and cortical regions of the brain and interact with the hypothalamus-
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pituitary-adrenal axis (Yohn et al., 2017). Because the SERT-inhibiting antidepressant drugs need
time to downregulate the 5-HT receptor, a direct antagonist yields a faster antidepressant response
in rats (Yohn et al., 2017).

Tricyclic Antidepressants (TCAs)
As with the MAOIs, the mood-altering properties of the tricyclic antidepressants (TCAs)
were also discovered through serendipity.

In the 1950s, the phenothiazine compound

chlorpromazine was established to elicit antipsychotic effects while in clinical trials (Kuhn, 1958;
López-Muñoz et al., 2004) This resulted in a flurry of clinical trials to test the potential of prior
synthesized compounds with similar chemical structures, which led to the identification of the
TCA imipramine in 1956 (López-Muñoz and Alamo, 2009).

Ironically, initial testing of

imipramine with schizophrenics showed worsening of symptoms but it was noted that depressed
schizophrenics appeared to have a positive mood change after a couple weeks of treatment (LópezMuñoz and Alamo, 2009). Imipramine was the first TCA approved by the FDA to treat depression
in 1959 (Hillhouse and Porter, 2015).
The TCAs currently approved for depression by the FDA include amitriptyline,
amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine
(Figure 1.3) (Food and Drug Administration; Chockalingam et al., 2019). The TCAs inhibit the
SERT and the norepinephrine transporter (NET), and to a lesser extent the dopamine transporter
(DAT) (Tatsumi et al., 1997; Penmatsa et al., 2013; Yohn et al., 2017). Their antidepressant
effects are thought to be primarily a result of the SERT and NET blockage, acting similar to lateridentified serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants (Gillman, 2007).
The TCA drug class is plagued by safety concerns including potentially fatal cardiovascular effects
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and CNS toxicity, which are observed at high plasma concentrations due to off-target receptor
promiscuity. Nortriptyline is thought to be the safest TCA (Gillman, 2007).

Table 1.3: Chemical structures of the TCAs.

Serotonin Selective Reuptake Inhibitors (SSRIs)
The MAOIs and the TCAs elevate monoamine levels through inhibition of enzymatic
degradation (MAOIs) or reuptake into the neuron (TCAs). Further support of the involvement of
the monoamines came from reserpine, a VMAT2 inhibitor that depletes monoamine
neurotransmitter levels, resulting in behavioral effects similar to depression (Pletscher et al., 1955;
Chessin et al., 1957; López-Muñoz and Alamo, 2009). It was speculated in the early 1970s that
selective inhibition of SERT would be an effective antidepressant strategy and led to the discovery
of the selective serotonin reuptake inhibitor (SSRI) fluoxetine (ProzacTM) by researchers at Eli
Lilly in 1975 before receiving FDA approval in 1987 (Tatsumi et al., 1997; Wong et al., 2005).
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The success of the SSRIs proved that serotonin was the primary monoamine neurotransmitter
responsible for the alleviation of depression. In addition, the SSRIs were found to have a safer
pharmacological profile, lacking the norepinephrine-based cardiovascular side effects commonly
found with the TCAs (Ferguson, 2001). Not surprisingly, SSRIs became the first-line
pharmacological treatment for depression. The SSRIs currently approved by the FDA to treat
depression include citalopram, escitalopram, paroxetine, fluoxetine, fluvoxamine and sertraline
(Figure 1.4) (Food and Drug Administration).

Table 1.4: Chemical Structures of the SSRIs.

Monoamine Transport Proteins: Serotonin Transporter
The SSRIs are competitive inhibitors of the SERT protein, one of the monoamine
transport proteins (MATs) that includes the DAT and NET. The MATs are plasma membranebound transporters responsible for terminating neuronal signaling of their endogenous substrate
(Aggarwal and Mortensen, 2017). The MATs belong to the solute carrier 6 (SLC6) family of 20
genes. This family encodes secondary active transporters that couple movement of
8

neurotransmitters with Na+ down their concentration gradients (Kristensen et al., 2011). The
SLC6A4 gene encodes the 630 amino acid SERT protein expressed in the CNS, peripheral nervous
system (PNS), placenta, epithelium, and blood platelets (Kristensen et al., 2011; Iurescia et al.,
2017). The MAT proteins are expressed on the presynaptic terminal of their respective neurons
(Lin et al., 2011; Aggarwal and Mortensen, 2017).
Structurally, the MATs are composed of 12 transmembrane domains (TM) that are
interconnected

by

a

series

of

extracellular and intracellular loops
as well as extended intracellular
amino (N-) and carboxyl (C-)
terminal tails (Figure 1.1) (Penmatsa
et al., 2013; Coleman et al., 2016;
Coleman and Gouaux, 2018). The
substrate transport mechanism is
characterized by alternating access
of the substrate/ion pore to the
intracellular and extracellular sides
of the cell membrane. This is
achieved with a progression of
structural conformations that make

Figure 1.1: Structural Overview of the MATs. The 12
transmembrane domains (TMs) that define the MAT structure are
color coded [TM1 (teal), TM2 (dark green), TM3 (silver), TM4
(dark orange), TM5 (pink), TM6 (light blue), TM7 (light orange),
TM8 (magenta), TM9 (yellow), TM10 (light green), TM11 (red),
TM12 (dark blue)]. Intracellular (bottom) and extracellular (top)
loops (black) connect the TMs and indicate orientation of the protein
within the lipid bilayer. Midway through the bilayer is the S1
binding site occupied by citalopram (yellow oval). The allosteric/S2
site (blue oval), also occupied by citalopram, is in the vestibule that
leads into the S1 site.
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Figure 1.2: Alternating Access Mechanism of Monoamine Transport. The MATs undergo a
conformational change during substrateAtransport with initial binding occurring with an outwardfacing conformation open to the extracellular side of the membrane (A; dDAT protein, PDB id.
4M48). Substrate and ion cofactor binding trigger a conformational change to an occluded state
(B; LeuT protein, PDB id. 2A65) before adopting an inward-facing structure (C; LeuT protein,
PDB id. 3TT3) and release of the substrate into the cell. The reset transition back to the outward
facing conformation is the rate-limiting step of transport.
up the transport cycle (Figure 1.2) (Forrest et al., 2008). Per the alternating access mechanism,
one of the conformations is an “outward-facing” (OF) structure that is open to the extracellular
side of the lipid bilayer (Wang et al., 2015). The substrate enters the OF structure through a
vestibule (Figure 1.3) that leads into the orthosteric binding pocket (S1 site) located roughly
midway through the protein (Figure 1.1) (Cheng and Bahar, 2015). An allosteric binding pocket
has been proposed to reside within the vestibule that would affect the binding kinetics of the
molecule within the S1 site (Coleman et al., 2016). While the MATs display both the S1 and S2
site, the specific residues that make up the sites differ by each protein and will be further discussed
in later sections. Entry of the substrate into the primary binding pocket triggers a conformational
change of the protein to an occluded structure (closed to both extracellular and intracellular sides)
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A.

B.

Figure 1.3: Vestibule Leading into the S1 Binding Pocket. A top-down view from the
extracellular side of the SERT protein (PDB id. 5I73) using a surface map (Panel A). Outlined
by a yellow box is the vestibule that leads into the S1 or orthosteric binding pocket. A closeup of the vestibule (Panel B) has citalopram (yellow) bound in the S1 pocket.
before opening to the intracellular side (“inward-facing” structure; IF) and releasing substrate and
Na+ (Coleman et al., 2019). A K+ ion is exported potentially through a channel-like mechanism
during the reset of the SERT protein from the IF to OF conformation, although it is unclear why
the K+ ion is unnecessary for the DAT and NET proteins (Adams and DeFelice, 2002; Aggarwal
and Mortensen, 2017). The SSRIs bind to the orthosteric binding pocket and typically lock the
transporter in the OF conformation, although some SSRIs including citalopram also occupy the
allosteric site and prevent the inhibitor in the S1 pocket from dissociating from the protein
(Coleman et al., 2016).
Surface expression of the SERT protein can be downregulated by chronic exposure to
its substrate serotonin, which could be effected by the activity of protein kinase C (PKC), cGMPdependent protein kinase (PKG) or p38 mitogen-activated protein kinase (MAPK) (Jørgensen et
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al., 2014). Changes in SERT surface expression due to serotonin exposure were blocked by the
antagonist citalopram (Jørgensen et al., 2014). Dimerization of the SERT protein can occur and
is an important regulator for trafficking the protein into Golgi vesicles for storage (Kilic and
Rudnick, 2000; Sitte et al., 2004). Although the SERT exists as dimers and oligomeric complexes
of up to 8 subunits in the plasma membrane that are stable for up to 10 minutes, its impact is
currently unknown and the monomeric form of the protein appears to be the functionally active
one (Anderluh et al., 2014; Coleman et al., 2016; Cheng and Bahar, 2019). The relative expression
of the oligomers in the plasma membrane is not affected by the SSRI antidepressants or cocaine
analogs (Schmid et al., 2001). The oligomeric complexes do not exchange subunits between
complexes, which could suggest that they are the result of the initial placement within the
membrane (Anderluh et al., 2014). Additionally, the depletion of bilayer cholesterol, a molecule
necessary for the functional activity of transport, did not alter the distribution of the oligomers in
the membrane (Anderluh et al., 2014). SERT molecules in dimers found during crystallization
were inverted positioning relative to each other, but this is believed to be an artifact of the
crystallographic conditions (supplementary material of Coleman et al., 2016). Computational
modeling of SERT dimers suggests that TM 12 is the likely subunit connection point (Periole et
al., 2018).
The SSRI antidepressants are antagonists of the SERT protein and prolong serotonergic
signaling within the CNS (Immadisetty et al., 2013). An early attempt to explain the mechanism
behind the antidepressant effects of the SSRIs and the TCAs is the monoamine hypothesis of
depression, which posits that depression is a result of a deficit of the monoamine neurotransmitters
including serotonin in the brain (Krishnan and Nestler, 2008; Haase and Brown, 2015). It was
noted that some violent suicide victims were reported to have low serotonin levels at the time of
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death (Shaw et al., 1967; Bourne et al., 1968; Immadisetty et al., 2013). The monoamine
hypothesis is too simplistic of a model, however, to entirely encompass the mechanism behind the
antidepressant effects shown by the SSRIs. One criticism of the hypothesis is the latency period
of weeks to months of MAT inhibitor antidepressant treatment required before relief from the
depressive symptoms occurs, even though these drugs cause an immediate increase in synaptic
serotonin levels (Insel and Wang, 2009). A rationale offered for this latency period has been that
the activation of inhibitory serotonergic autoreceptors (5HT1 family) in response to the increased
serotonin levels depresses serotonergic signaling (Yohn et al., 2017). Long term SSRI treatment
causes desensitization of these autoreceptors and changes in receptor expression that would
eventually promote increased serotonergic signaling. This explanation ignores the fact that several
postsynaptic 5-HT receptor types associated with antidepressive effects would still be immediately
activated by the serotonin surge upon first taking the SSRI and is a desperate attempt to rationalize
the monoamine hypothesis. The currently favored mechanism for the antidepressant effects shown
by the SSRIs is the neurotrophic hypothesis and its role in adult hippocampal neurogenesis (Jacobs,
2002). Some postmortem studies have reported reductions in the volume of the prefrontal cortex
and hippocampus of depressed patients (Krishnan and Nestler, 2008). The SSRIs are thought to
elicit adult hippocampal neurogenesis through an increase in the expression of brain-derived
neurotrophic factor (BDNF) in the hippocampus, which is regulated by the transcription factor
cAMP response element binding protein (CREBP), altering gene transcription (Figure 1.4) (Haase
and Brown, 2015). The activation of both the 5HT1A and the 5HT4 receptors has been found to
increase neurogenesis in the dentate gyrus over weeks, and play a role in the antidepressant
response found in rodent models (Mendez-David et al., 2014; Samuels et al., 2015). The recently
FDA-approved fast acting antidepressant ketamine, a repurposed anesthetic, is thought to increase
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neurogenesis through similar pathways downstream of the serotonin receptors, although ketamine
has potential for abuse and can cause cognitive decline (Clarke et al., 2017).

Figure 1.4: Neurogenesis Pathway. The SSRI antidepressants inhibit SERT on the
presynaptic neuron (1), which leads to an increase in 5HT (2) within the synapse. Activation
of postsynaptic 5HT1A and 5HT4 receptors (3) lead to the phosphorylation of CREB (4) within
the nucleus and promote the synthesis of BDNF (5) ultimately leading to hippocampal
neurogenesis.

Premise of this Research
The United States Center for Disease Control (CDC) depression data from 2011-2014
suggests that over 12% of people over the age of 12 have used antidepressants within the last
month, an increase of 5% since the 1999-2012 survey (Pratt et al., 2017). Additionally, roughly
25% of people that used antidepressants have been taking them for more than 10 years (Pratt et
al., 2017). The side effects of the first line SSRI antidepressants, including lack of efficacy and
prolonged latency periods with many adverse effects before therapeutic relief, often make
medication adherence a problem. This establishes the necessity for the identification of novel
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inhibitors that offer the possibility of alternative therapeutic profiles compared to the SSRIs. Some
design strategies have included the serotonin-norepinephrine reuptake inhibitors, and multimodal
antidepressants such as vortioxetine and vilazodone, which modulate other serotonergic receptors
in addition to SERT (Gillman, 2007; Andersen et al., 2015; Wang et al., 2016). The Surratt and
Madura laboratories have approached antidepressant drug discovery by combining computational
chemistry modeling of drug targets in the brain with classical pharmacological methods to identify
potential inhibitors of the SERT protein (Manepalli et al., 2011; Nolan et al., 2011; Nolan et al.,
2014).
Computational Drug Discovery
The drug discovery process is focused on identifying pharmacologically active compounds
with novel chemical structures that can be developed into potential candidates for clinical trials.
The development of drug candidates is exceedingly expensive with an average cost over 2 billion
dollars as of 2010 (Nicolaou, 2014; Mohs and Greig, 2017). Successful candidates take roughly
13.5 years to receive FDA approval, with under 10% of small molecules being approved
(Nicolaou, 2014; Mohs and Greig, 2017). Roughly a third of the cost is spent on the preclinical
development including target identification (initial decision of potential targets), target validation
(confirmation of the target’s involvement in the disease state), initial molecule discovery,
structure-activity relationships (SARs), in vitro and in vivo pharmacological testing, toxicity and
pharmaceutics testing (Nicolaou, 2014; Dahlin et al., 2015). One established strategy to identify
potential candidates is high-throughput screening (HTS), which utilizes automation to screen
chemical libraries, curated collections containing thousands of compounds with diverse structures,
against a target protein to identify compounds that meet the set criteria of the assay (Saha et al.,
2018). HTS generally allows for 10,000 to 100,000 compounds to be screened per day due to the
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miniaturization of assays, allowing more compounds to be screened in parallel through continuing
advancement of robotics (Inglese et al., 2007). Processing the data is a common problem
associated with HTS due to the vast amount of data generated, and common approaches to handle
this include grouping compounds by chemical diversity and unique biological profiling, which is
determined by performance in cell-based assays looking at attributes such as gene expression or
cell morphology (Wawer et al., 2014; Saha et al.,
2018).

In addition, the sheer cost of HTS is

considered to be well beyond the capabilities of
typical academic researchers, a compelling reason to
incorporate computational modeling into the drug
discovery process (Wasko et al., 2015).
The major computational approaches to drug
discovery are ligand-based or structure-based (Figure
1.5). The ligand-based method, the only choice when
the structure of the drug’s target is unknown, employs
established ligands of the target receptor as templates
that guide the design and synthesis of a SAR series of
analogs, and in this way identifies common structural
elements that are essential to their functional activity
(Badalà et al., 2008).

Typically, the active

compounds are superimposed and a pharmacophore is
created. A pharmacophore is a model of the chemical
interactions between ligand and receptor necessary
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Figure 1.5: Comparison of LigandBased and Structure-Based Drug
Design. Ligand-based approaches utilize
known ligands to build a pharmacophore
based on key chemical features (A). The
created pharmacophore is highlighted by
spheres indicating aromaticity, hydrogen
bond donors, and hydrogen bond
acceptors. Structure-based approaches
utilize the receptor’s structure (backbone
displayed in red) to evaluate the
compound’s interactions within the
binding pocket (green) (B).
Figure
adapted from Wasko et al., 2015.

for the desired efficacy, which can be computationally modeled by combining common chemical
attributes such as hydrogen bond donor / acceptor potential and hydrophobicity based on known
ligands, and can be used to screen for molecules that match the pharmacophore’s criteria (Ferreira
et al., 2015). Creating a pharmacophore is useful for both methods, but critical for the ligandbased search strategy. The structure-based approach utilizes a computational model of the target,
usually a protein, to guide drug discovery.

Structural Biology of the MATs
The three-dimensional structure of a receptor protein can be elucidated using x-ray
crystallography, nuclear magnetic resonance spectroscopy (NMR), and cryogenic electron
microscopy (cryo-EM) (Yee et al., 2005; Doerr,
2017). Crystal structures solved by x-ray diffraction
are the most common structure-based ligand
screening tools, and are curated by the Protein Data
Bank (Berman et al., 2000). These structures are
considered “snapshots” of receptor conformations,
rigid structures obtained under non-physiological
conditions. These proteins often have site-directed
amino acid sequence mutations introduced to aid

Figure 1.6: Electron Density of the
DAT (4XP1). The electron density is
displayed as blue mesh for the DAT
structure. The crystallographer fits the
side chains and ligand dopamine to the
electron density. Figure adapted from
Madura, 2016.

crystallization with the goal of not appreciably
affecting ligand binding sites or protein expression (Piscitelli et al., 2015). This is not always the
case; one mutation (T439S) located within the S1 binding pocket of SERT (PDB id. 5I6X) altered
the binding of paroxetine (Coleman and Gouaux, 2018). An electron density map of the crystalized
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protein is determined based on the diffraction pattern of the x-ray beam, which is used by the
crystallographer to position
the elemental structure of
the protein based on the
known amino acid sequence
(Figure 1.6) (Lang et al.,
2014). The resolution of the
model is determined by the
confidence and probability
of the structure’s fit to the
election density map, with

Table 1.5: Guide to protein crystal structure resolution.
Table is adapted from Madura, 2016.

lower Ångstrom structures
representing a better fit (see Table 1.5; (Madura, 2016)) (Piscitelli et al., 2015). Proteins are
inherently fluid molecules, and membrane-bound proteins like the MATs are difficult to crystalize
because of the absence of a lipid bilayer to stabilize the protein’s physiological 3D structure. The
recently crystalized Drosophila DAT and the human SERT crystal structures have a resolution
around 3 Å, which would allow the crystallographer to successfully orient the backbone of the
protein structure (Wang et al., 2015; Coleman and Gouaux, 2018). In comparison, many of the
GPCRs, specifically the adrenergic receptors, have a resolution under 2 Å, in which case the side
chains within the binding pocket can be accurately positioned. To achieve this resolution, the
external loops are often truncated (Zhang et al., 2015). Until the human SERT crystal structures
were published in 2016, structure-based studies relied on building homology models of the protein,
using an evolutionarily-related protein as a structural template (Fiser and Šali, 2003). To build a
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homology model, the amino acid sequences of the target protein and the template structure are
aligned and compared using sequence identity (percent of amino acids conserved) and sequence
similarity (percent of amino acids within the same class) (Hillisch et al., 2004; Wasko et al., 2015).
The higher degree of similarity between the target protein and the template is indicative of a better
structural template for a homology model. The first credible crystal structure available as a
template for the MATs was that of the LeuT bacterial leucine transporter (Yamashita et al., 2005).
Structural Templates of the MATs
LeuT
Although LeuT only shares 20-25% of its
amino acid sequence (sequence identity) with MAT
proteins, the first deposited LeuT structure (2A65)
within the PDB confirmed the existence of the 12 TM
domains (Figure 1.7) (Yamashita et al., 2005). The
2A65 structure was defined as being in an occluded
state by the closure of an external gate partially
comprised of R30 (TM 1) and D404 (TM 10) (Figure
1.8).

Figure 1.7: LeuT crystal structure.
LeuT (red; PDB id. 2A65) is shown
with the substrate leucine (grey)
within the S1 binding pocket.

Co-crystallized were the endogenous substrate

leucine along with the two Na+ ions required for substrate
transport within the S1 binding pocket, buttressed by
TMs 1, 3, 6 and 8 and an enclave formed by kinks within
TM domains 1 and 6, located roughly 6 Å from the
extracellular border of the lipid bilayer (Figure 1.10)
(Yamashita et al., 2005).

Unexpectedly, the LeuT
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Figure 1.8: External Gate of LeuT.
R30 (yellow) and D404 (blue) define
the external gate above the S1 binding
site occupied by leucine (gray).

structure revealed a tertiary motif known as the “LeuT fold”, which identified that TM 1-5 and 610 form a pseudo repeat that could be superimposed when
rotated by 176.5o, with the remaining TM domains (11-12)
not being essential for transport of the substrate (Figure 1.9)
(Yamashita et al., 2005). Interest in LeuT substantially
increased in 2007 with the publication of LeuT structures
that were co-crystalized with the tricyclic antidepressant
clomipramine (Singh et al., 2007). Clomipramine acted
as a non-competitive allosteric modulator that sat
approximately 11 Å above the S1 binding pocket and

Figure 1.9: LeuT Fold. The LeuT fold
is comprised of an inverted repeat
consisting of transmembrane domains
1-5 (blue) and 6-10 (red).

altered the kinetic rates of the leucine
molecule by stabilizing the extracellular gate
(Singh et al., 2007). Separately, Shi et al.
argued for the existence of a secondary
substrate (S2) site in the same vicinity. Using
steered molecular dynamics simulations,
they postulated that substrate occupation of
the S2 site was necessary to trigger the
conformational transitions for transport (Shi
et al., 2008). This view was contested by
Gouaux and colleagues, who argued for only

Figure 1.10: S1 Binding Pocket TM Domains.
TM1 (red), TM3 (green), TM6 (blue) and TM8
(purple) form the S1 binding pocket co-crystalized
with leucine (grey) within the LeuT crystal structure
(PDB id. 2A65).

one high affinity binding pocket on LeuT (Piscitelli et al., 2010). Using isothermal titration
calorimetry to measure the thermodynamic response and stoichiometry of L-leucine binding to
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LeuT, only a single high affinity site (S1) was detected. They acknowledged that the allosteric
site may have lower affinity to lead the leucine substrate into the high affinity site, but stopped
short of agreeing that a secondary leucine site was needed to trigger release of the substrate
(Piscitelli et al., 2010).
The alternating access transporter mechanism is based on the adoption of at least three
distinct conformational states of the protein during the substrate translocation cycle (Forrest et al.,
2008). An outward-facing (OF) transporter structure open to the extracellular side would allow
the substrate and necessary ions to bind in the S1 pocket, triggering conversion to the S1-occluded
structure identified in the 2005 LeuT crystal structure (PDB id. 2A65), before shifting again to
adopt an inward-facing (IF) structure to release the substrate and ion cofactors into the cytoplasm
(Yamashita et al., 2005; Piscitelli et al., 2010). In 2012, crystal structures of LeuT in substratefree (apo) OF and IF conformations provided more insight into the translocation cycle
(Krishnamurthy and Gouaux, 2012). The OF structure (PDB id. 3TT1) appeared to rely on a hingelike mechanism pivoting on V23 (TM1), G55 (TM2), and L257 (TM6) to adopt an OF structure
compared to the occluded structure (Krishnamurthy and
Gouaux, 2012).
LeuBAT
TCAs,

SSRIs,

and

serotonin-norepinephrine

reuptake inhibitors (SNRIs) bind non-competitively to the
extracellular vestibule in the LeuT protein, but this is now
thought to be artifactual and not reflective of the
competitive binding of these compounds to the
human MATs (Rudnick, 2007; Wang et al., 2013).
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Figure 1.11: LeuBAT Crystal Structure
(PDB id. 4MM5). LeuBAT (dark blue) was
crystalized with the SSRI sertraline (grey)
within the S1 binding pocket. The amino acids
within the S1 binding pocket were mutated to
those of SERT, which shifted the
antidepressant binding site on LeuT from S2 to
S1.

To identify key S1 pocket residues for BAT (biogenic amine transporter; i.e., MAT) ligand
recognition, MAT residues believed to be important for ligand binding systematically replaced the
corresponding LeuT residues to form LeuBAT in hopes of simulating the competitive binding of
known MAT ligands. The LeuT and hSERT amino acid residues within the S1 binding pocket
were compared to identify probable residues imparting SERT selectivity. In total, 20 amino acids
were mutated to result in 12 LeuBAT crystal structures that bound TCAs, SSRIs, and SNRIs within
the S1 binding pocket (Figure 1.11) (Wang et al., 2013). While the LeuBAT structures were an
improvement over LeuT as templates to study the SERT protein, they were rapidly overshadowed
by the publication of a fruit fly DAT structure (Penmatsa et al., 2013).
dDAT
The 2013 Drosophila dopamine transporter (dDAT; PDB id. 4M48) was co-crystalized
with the tricyclic antidepressant nortriptyline
bound in the S1 binding pocket formed from TMs
1, 3, 6 and 8 (Figure 1.12) (Penmatsa et al., 2013).
The dDAT structure shares more than 50% of its
amino acid sequence with the human MATs and
was solved at a resolution of 3.0 Å through use of
five stabilizing mutations (Penmatsa et al., 2013).
Overall, the structure was locked in an OF
conformation with the TCA inhibitor blocking
substrate access to the central binding pocket.
The crystal structure displayed the LeuT fold
motif, but notably deviated with a kink at P572
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Figure 1.12: dDAT Crystal Structure
(PDB id. 4M48). dDAT co-crystalized with
the TCA nortriptyline within the S1 binding
pocket (dark grey). Differing from the LeuT
structures is a kink in TM12 highlighted in
green. A cholesterol molecule (blue) is
located near TM 1, 5, and 7.

in TM 12 that forced the second half of the TM away from the protein (Penmatsa et al., 2013).
This kink in TM 12 was later seen in the structures of the human serotonin transporters, which was
co-crystalized with a cholesterol molecule within the kink of TM12 (Coleman et al., 2016). A
cholesterol molecule was identified on dDAT within a pocket comprised of TMs 1, 5, and 7 and
is speculated to play a role in stabilizing the OF structure. Consistent with this idea, increased
cholesterol concentrations in lipid membranes stabilize OF structures (Hong and Amara, 2010;
Penmatsa et al., 2013).
Later efforts in 2015 led to the crystallization of dDAT complexed with substrates, their
analogs, and inhibitors including dopamine, its analog 3,4-dichloroophenethylamine (DCP), and
psychostimulants (D-amphetamine, methamphetamine, cocaine, B-CFT, and RTI-55) (Wang et
al., 2015).

Functional transport of dopamine was regained by reintroducing three of the

thermostability mutations (V275A, V311A, and G538L) and extracellular loop 2 in the new dDAT
construct (Wang et al., 2015). In addition, mutations within the binding pocket at TM 3 (D121G)
and TM 8 (S425M) were introduced to mimic the human
DAT structure (hDAT) (Wang et al., 2015). All of the
ligands were co-crystalized while within the orthosteric
binding pocket of the dDAT structures. The substrate
dopamine was crystalized in an OF DAT structure with the
charged amine interacting with the TM 1 D46 (equivalent
of D79 in hDAT), the catechol group hydrogens bonding
with A117, and the remainder sitting in a hydrophobic

Figure 1.13: DAT Binding Pocket.
DAT (PDB id. 4XP1) with dopamine
within the S1 binding site.

pocket consisting of A121, Y124, S422, and F325 (Figure 1.13). Interestingly, two water
molecules were observed within the binding pocket with dopamine but were not observed with
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DCP bound, which formed a partially occluded OF structure with F319 rotating to occlude the
binding pocket.

The amine group of DCP formed a hydrogen bond with D46 while the

dichlorophenyl ring interacted with V120 and F325. Both D-amphetamine and methamphetamine
stabilized OF conformations from within the S1 binding pocket. Cocaine was crystalized within
the S1 binding pocket, forming a salt bridge with D46 and aromatic interactions with F325 (Wang
et al., 2015).
hSERT
After multiple attempts to crystalize the human SERT (hSERT) protein were unsuccessful,
two site-directed mutations (I291A and T439S) were added to enhance thermostability (TS2
construct) and structures were crystalized at a resolution of 4.5 Å (Green et al., 2015; Coleman et
al., 2016). A third thermo-stability mutation (T110A) was necessary to enhance the resolution of
the structures to 3.15 Å (TS3 construct). Unfortunately, the TS3 construct was locked in the OF
conformation and was functionally inactive by failing to transport serotonin. Six hSERT crystal
structures are deposited within the PDB
with the reference codes 5I6X, 5I67, 5I73,
5I74, and 5I75.
structures

were

The initial crystal
co-crystalized

with

citalopram and paroxetine within the
binding pocket.

Additionally, a Br-

citalopram molecule was found within an
allosteric site directly above the S1 site,
similar to the LeuT structure with the TCA

Figure 1.14: SERT S2 Binding Site. Citalopram
(grey) is shown within the S2 binding site of SERT
(PDB id. 5I73).

clomipramine (PDB id. 2Q6H) (Singh et al., 2007). This allosteric site is thought to affect the
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kinetic off-rate (Koff) of the citalopram molecule within the S1 site and extend the time bound to
SERT (Coleman et al., 2016). The S2 site sits above two external gates formed by amino acids
Y176 / F335 and R104/E494 (Coleman et al., 2016). Citalopram within the S2 site forms an
aromatic interaction with F335 and an ionic interaction with E494 (Figure 1.14). Additionally,
residues R104, D328, A331, and Y556 were
reported to make up the S2 site (Coleman et al.,
2016). The TS3 construct contained the T439S
mutation within the S1 binding pocket altered the
binding of some antidepressants. Later efforts to
crystalize SERT with the wild type T439 residue
resulted in structures cocrystalized with the SSRIs
paroxetine, fluvoxamine, sertraline, or S-citalopram
(Coleman and Gouaux, 2018).

Each antagonist

interacted with Y95, D98, I172, Y176, F335, F341,

Figure 1.15: SERT S1 Binding Site.
Citalopram (grey) is shown within the
S1 binding site of SERT (PDB id.
5I73). An Na+ ion is displayed in
orange.

and T439 within the binding pocket (Coleman and Gouaux, 2018). The S1 site is sometimes
broken down into three subsites: A (Y95, D98, S336, S438), B (A173, Y176, N177, T439, G442)
and C (I172, F334, F341, T497, V507) (Zeppelin et al., 2019).
Moving beyond SERT crystal structures locked in the OF conformation, cryo-electron
microscopy was used to study the conformational changes of the protein (Coleman et al., 2019).
Ibogaine, a purported anti-addiction drug with low affinity to many receptors including SERT, was
utilized to establish changes from the OF conformation through the occluded structure before
adopting an IF conformation (Wasko et al., 2018; Coleman et al., 2019). Ibogaine is a noncompetitive inhibitor of serotonin transport but is a competitive inhibitor against antidepressants
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for the primary binding site. At the functional TS2 SERT construct, ibogaine had a Kd of 400nM,
while the OF-locked TS2 variant had a reduced Kd of 5-8 µM (Coleman et al., 2019). This fits
with the proposed model allowing ibogaine to enter the S1 site through the OF structure before
adopting the preferred IF conformation.
The work in this dissertation utilizes the crystal structure of the hSERT protein for virtual
(in silico) screening for new compounds with affinity for the S1 (orthosteric) binding pocket
(Coleman et al., 2016). It was hypothesized that inhibitors with novel chemical scaffolds could
be identified through the computational modeling. Chapter 2 details the computational modeling
used to successfully identify inhibitors of the SERT protein. The in vitro pharmacological analysis
of the compounds that were purchased is contained in Chapter 3.

26

Chapter 2: Computational Modeling to Identify Inhibitors of the Human SERT

Computational Virtual Screening
Computational drug discovery methods are utilized to identify interesting compounds
before pharmacological testing is completed (Sliwoski et al., 2014).

With structure-based

methods, virtual screening (VS) is a widely used technique once a protein target has been
established and a three-dimensional model created. VS is analogous to HTS, but uses ligand
docking, a computational technique that predicts the placement of the compound within the
binding pocket and estimates affinity to the receptor. Virtual chemical libraries of a million
molecules can be quickly screened for high affinity to the binding site of the target protein (Lionta
et al., 2014; Sliwoski et al., 2014). The enormous equipment and chemical compound costs with
HTS are not seen with virtual screening, and the latter provides a significant cost advantage by
filtering out unlikely compounds before purchase / synthesis. The predictive accuracy of the
virtual screen hinges on the docking software.
Docking software is available as open-source academic programs (Autodock suite), and
from commercial vendors including Chemical Computing Group (Molecular Operating
Environment; MOE), Schrödinger (Glide), and BioSolveIT (FlexX) (Pagadala et al., 2017).
Ligand-protein docking is classified based on the flexibility of both the ligand and protein side
chains: “rigid-rigid” (both inflexible), “rigid receptor” (ligand flexibility alone), and “flexible
receptor” (allowing both ligand and protein to be flexible) (Pagadala et al., 2017). Rigid receptor
docking is considered a standard approach by many pharmaceutical companies due to the
additional computational resources necessary for flexible receptor docking (Andrusier et al.,
2008).
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In order to sample the binding event in a time-effective manner, the docking programs do
not account for the higher-order physics such as quantum or statistical mechanics, but rather rely
on using approximations called scoring functions to place and rank the binding of ligands to the
receptor.

Scoring functions are classified into four categories: force field (physics)-based,

empirical-based, knowledge-based, and descriptor-based (Liu and Wang, 2015). Force field-based
scoring functions attempt to account for the changes in energy due to van der Waals effects (effects
of non-polar interactions), electrostatics (effects of charged interactions), hydrogen bonding, and
sometimes solvation (Lionta et al., 2014; Liu and Wang, 2015). Empirical-based scoring functions
place weight on positive interactions regarding hydrogen bonding, lipophilicity, and metal ions,
while placing penalties on steric clashes and the hindrance of rotatable bonds (Lionta et al., 2014;
Liu and Wang, 2015). Knowledge-based scoring functions are built using training sets of ligands
bound to receptors to examine the average contacts between ligands and receptors to identify
favorable and unfavorable interactions (Huang and Zou, 2008). The descriptor-based scoring
functions incorporate machine learning techniques to build models based on certain descriptors
such as number of hydrogen bonds, or by creating chemical fingerprints of the ligand interactions
within the binding site (Liu and Wang, 2015). Currently, scoring functions are often able to
identify the correct binding pose, but often struggle with accurately ranking predicted binding
affinity (Lionta et al., 2014). As a result, it is crucial to thoroughly evaluate the scoring functions
for the target protein using training sets of both binding and non-binding compounds before
completing the virtual screen (Lagarde et al., 2015).
Computational Approach
With the stated goal of identifying novel inhibitors of SERT, a computational approach
was taken to complete a structure-based virtual screen within the S1 binding pocket of the SERT
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crystal structure. MOE software was chosen to complete the virtual screen based on initial
benchmarking with a test set composed of SERT compounds with known affinity. The scoring
functions within the docking module of MOE were analyzed to identify the appropriate parameters
for the screen. The Maybridge Hit Discoverer, a compound structure collection distributed by
ThermoFisher, was chosen as the library to be screened due to the affordability (compounds cost
under $80), commercial availability, and curation date. The top-ranking compounds were filtered
utilizing the Lipinski Rule of 5 and estimated binding affinity by the docking protocol. The top
44 compounds were assessed for structural uniqueness using the Tanimoto coefficient with the top
10 compounds purchased for pharmacological testing.
Methodology
SERT Computational Model Preparation
A mutant human SERT crystal structure (Figure 2.1A; PDB id. 5I71, 3.15 Å resolution) was
downloaded from the Protein Data Bank(Coleman et al., 2016). Mutated residues within the
structure were reverted to the wild type amino acid sequence from the UniProt sequence database
using the Molecular Operating Environment (MOE) software (version 2018.01.01; Chemical
Computing Group, 2017). Refinement of the SERT structure (Figure 2.1B) was completed
through molecular dynamics simulations using the CHARMM36 forcefield with 1-palmitoyl-2oleoylphosphatidylcholine (POPC) lipid membrane, solvated with TIP3P water at a 0.15M NaCl
concentration with a temperature of 310K (Harvey et al., 2009). The simulation was completed
with ACEMD software for 40 ns until the backbone root-mean-square deviation (RMSD)
converged, and the resulting structure was used as the starting point for the docking simulations
(Figure 2.1C). The Structure Preparation module within MOE was utilized with side chains
protonated using the Protonate 3D setting with the Amber 14:EHT forcefield, and structural issues
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/ warnings were resolved. Since sodium atoms are often required for ligand binding, the 2 sodium
atoms and 1 water molecule found within the crystal structure were reinserted into the binding
pocket and the system was minimized using MOE (Aggarwal and Mortensen, 2017). The
orthosteric binding pocket (S1 site) was identified using the Site Finder module using Alpha
Spheres, and dummy atoms were placed within the binding pocket (Figure 2.1D). This site
corresponded to the second binding pocket predicted by the software.
Virtual Screening (Docking) Protocol
The docking simulations were completed using MOE software 2018.01.01 using the Dock module.
Initial protocol validation was completed using a test set of 24 compounds with experimentally
determined binding affinity for SERT ranging from high micromolar to low nanomolar, which was
converted into a free energy value (kcal). (Table 2.1) (Tatsumi et al., 1997). The Pearson
correlation coefficient was used to compare the predicted affinity to the experimental affinity using
JASP software. The following settings used for the docking simulations included selecting the
orthosteric binding pocket, use of a wall constraint around the pocket, and use of a structural
pharmacophore on the oxygen atom of aspartic acid-98 (D98. DON2 with an R of 2). Ligands
were selected out of preconstructed MOE database (MDB) files, and docking was carried out using
the triangle matcher mode with the ASE scoring function retaining 10 poses. The poses were
refined using induced fit (flexible side chains) with the London dG scoring function; one pose was
selected for further work. The protocol for the VS study was validated using the 24-compound
test set using the Pearson, Spearman, and Kendall correlation tests with JASP software.
Chemical Library
The Maybridge Hit Discoverer compound structure collection corresponding to 51,775
commercially available compounds was acquired from ThermoFisher. The collection was rebuilt
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into 3-dimensional coordinates with the addition of hydrogen atoms and protonated at a pH of 7
using MOE software.
Analysis of Virtual Screen
The resulting output of the virtual screen was filtered by predicted affinity (S score below -17
(initial filter) and -18(final filter)), chemical properties (Lipinski Rule of 5), and chemical
uniqueness using chemical fingerprinting (Tanimoto coefficient). The RDKIT toolkit from the
MayaChemTools software package was utilized to calculate the chemical fingerprinting and the
similarity.
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Results

Figure 2.1: Serotonin Transporter Model. The backbone of the SERT crystal structure (red
ribbons) co-crystalized with citalopram (PDB id. 5I71) within the S1 binding pocket and a
cholesterol molecule in the kink of TM 12 (A). The refined SERT structure used for the virtual
screen is shown in blue with the binding pocket highlighted with a surface map (B). An overlay
of the SERT crystal structure (red) and the refined model (blue) revealed a backbone RMSD of
3.5 Å (C). The surface map of the binding pocket is highlighted with the amino acid residues
shown in ball and stick form (D).
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Table 2.1: Computational Testset for Docking Benchmarking. The name, structure, and
experimental binding affinity of the 24 compound testset that was used to evaluate the
performance of the docking software for the predictability against SERT.
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Table 2.2: SERT Correlation Testing without Ions. The performance of the scoring
functions within the MOE software ability to predict binding affinity of the testset was
evaluated using the Pearson correlation coefficient. Initial benchmarking was completed
without the Na + ions within the S1 binding pocket. The scoring function combinations are
displayed in pairs with the first responsible for the placement and the second responsible for
rescoring the identified pose. The correlation function comparing the output of the docking
simulation to the experimental affinity is displayed as R along with R2.

34

Table 2.3: SERT Correlation Testing with Ions. The performance of the scoring functions
within the MOE software ability to predict binding affinity of the testset was evaluated using
the Pearson correlation coefficient. Initial benchmarking was completed with the Na + ions
within the S1 binding pocket. The scoring function combinations are displayed in pairs with
the first responsible for the placement and the second responsible for rescoring the identified
pose. The correlation function comparing the output of the docking simulation to the
experimental affinity is displayed as R along with R2.
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Table 2.4: Final Validation of the Docking Protocol with the Structural Pharmacophore.
After the structural pharmacophore was placed on D98, the docking protocol was re-evaluated
using the 24 compound test set using the Pearson, Spearman, and Kendall correlation tests. Each
compound is sorted by its experimental affinity (kcals) and displayed is the predicted affinity of
the docking simulation.
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Figure 2.2: Virtual Screening Protocol. The Maybridge Hit Discoverer chemical library was
chosen to be virtually screened within the S1 binding pocket of hSERT of which 30,247
compounds were scored and returned. In order to analytically choose the candidate compounds,
a series of filters including predicted affinity, the Lipinski Rule of 5, and structural uniqueness
were applied and 10 compounds were identified for purchase and pharmacological analysis.
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Table 2.5: Candidate Compounds Identified for Pharmacological Analysis. The
completed virtual screen identified 10 compounds that were selected for pharmacological
testing. The structure, catalogue identification number (Maybridge ID #.), and the predicted
affinity (S score) are displayed within the table.
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Results
Docking Software Benchmarking
Benchmarking studies were conducted to evaluate the performance of the scoring functions
in the MOE to differentiate between binders and non-binders. Initial testing was completed
without the two Na+ ions within the binding pocket. The Pearson correlation test was used to
assess the relationship between the predicted affinity and the experimental affinity. Each scoring
function combination for the flexible docking simulation (1st scoring function for placement and
the 2nd for rescore) was evaluated (Table 2.2). The Pearson R coefficient values ranged from 0.44
– 0.67 (R2 = 0.19 – 0.45) with the best correlation occurring with the scoring function combination
Alpha Hb – London dG. The scoring function combinations Affinity dG – London dG and
GBVI/WAS dG – GBVI/WAS dG failed midway through the simulation. The scoring functions
were next evaluated with the 2 Na+ ions found in the crystal structure to see if the correlation
improved (Table 2.3). The Pearson R coefficient values for the simulations with ions ranged from
0.30 – 0.73 (R2 = 0.09 – 0.54). The scoring function combination ASE – London dG achieved the
best correlation between predicted and experimental affinity.

Further benchmarking was

completed incorporating the ASE – London dG using a structural pharmacophore interaction with
D98 (Table 2.4). Correlation testing was completed with the Pearson (R = 0.737), Spearman (R =
0.792), and Kendall coefficients (R = 0.581). In addition, the data were visually inspected, with
nine of the top 12 compounds scoring under -13.5 and one compound of the bottom 12 ranking
under -13.5. Six out of the top nine compounds with experimental affinity were ranked under -14.
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Virtual Screen
The Maybride HitDiscoverer compound collection (51,775 compounds) was screened targeting
the S1 binding pocket of SERT, which resulted in 30,247 compounds being returned and scored
(Figure 2.2). A relatively small number (415) of the 30,247 were ranked by the docking software
to have a predicted affinity S score under -17. The compounds were further filtered by predicted
affinity (S score under -18) and the Lipinski Rule of 5, which brought the total to 44. The 44
compounds were examined for their chemical uniqueness assessed by the Tanimoto coefficient,
which determined the chemical similarity between each compound. It was determined that the 10
compounds with the unique chemical structures would be purchased for pharmacological testing
(Table 2.5).
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Discussion
Structure-based virtual screens targeting the human SERT have been successfully
completed using homology models based on the structural template LeuT (Manepalli et al., 2011;
Kortagere et al., 2013; Gabrielsen, et al., 2014; Nolan et al., 2014). The OF conformation of SERT
has been targeted in every virtual screen completed to date. The Surratt and Madura laboratories
have completed two virtual screens that used 2A65 as the template structure and targeting the S2
(Manepalli et al., 2011) or S1 (Nolan et al., 2014) pocket. A homology model based on 2QJU
targeted an allosteric site containing S2 but focused on extracellular loops 1 and 3 (Kortagere et
al., 2013). Since the OF structure is open to both the S1 and S2 sites, Grabrielsen et al. defined
both as the targeted sites during the virtual screen with a homology model based on 3F3A
(Gabrielsen, Rafal Kurczab, et al., 2014).
The original intent of this project was to build and refine a SERT model based on the then
recently published eukaryotic dDAT crystal structure due to its far greater sequence homology
compared to the bacterial LeuT (Penmatsa et al., 2013; Wasko et al., 2015). This appeared to be
the correct approach, as reported technical difficulties made the prospect of crystalizing the human
SERT appeared unlikely (Green et al., 2015). Homology models were constructed based on the
dDAT structure (PDB id. 4M48), co-crystalized with the TCA nortriptyline within the S1 binding
pocket, using MOE and MODELLER software (Eswar et al., 2007; Chemical Computing Group,
2017). Before a virtual screen could be completed, the hSERT crystal structures were published
and named by the number of thermostability mutations needed to improve stability during
crystallization (Coleman et al., 2016). The TS2 constructs were solved at a resolution of ~ 4.5 Å
while the construct containing the additional mutation (TS3) lowered the resolution to ~ 3 Å, but
locked the protein into the OF conformation and lacked functional ability to transport [3H]-
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serotonin in cellular models (Coleman et al., 2016). One mutation within the binding pocket
(T439S) hindered the binding of the SSRI paroxetine, which subsequent crystal structures restored
the T439 amino acid (Coleman and Gouaux, 2018). Since then, one virtual screen has been
completed using the OF SERT structure (PDB ids. 5I73 and 516X) targeting the S1 and S2 sites,
but no pharmacological analysis of the results was conducted (Erol et al., 2017).
The SERT structure co-crystalized with the SSRI citalopram (PDB id. 5I71) was chosen as
the starting point for this study due to its relatively high resolution (3.15 Å) and the ligand within
the S1 binding pocket. Comparison between the human SERT amino acid sequence from the
UniProt database and the 5I71 structure revealed 14 total mutations, which were corrected to the
wild-type sequence using MOE software. Refinement was completed through molecular dynamics
simulations occurring within a POPC membrane with TIP3P water and 0.15 mM NaCl to relax the
protein backbone with the CHARMM36 force field. The simulation was run for 40 ns using
ACEMD software, which was ended when the backbone RMSD converged at 3.5 Å compared to
the initial structure and was used as the SERT model for this study.
Virtual screens utilize docking calculations to timely differentiate compounds with affinity
and non-binders at the target protein. However, these simulations trade accuracy for speed.
Docking has success with the correct placement of ligands within the binding pocket, but often
struggles with accurately predicting relative affinity (Lionta et al., 2014). Proper validation of the
scoring functions within the docking software is crucial to determine the predictiveness of the
simulations to identify novel compounds. At the basic level, a comparison between the crystalized
ligand and the docked pose was used to evaluate Glide software (Erol et al., 2017). A more
thorough approach is to use a “seeded” library that contains compounds with known target affinity
within a library of non-binding and uncharacterized compounds. By seeding 10 inhibitors (SSRIs

42

or SNRIs) within 1990 unknown compounds, the MOE docking protocol placed six compounds
within the top 253 ranked compounds (Nolan et al., 2014). Ideally, the scoring functions would
rank the high affinity compounds as the top hits.
Pharmacophores have been applied to SERT screening, generated from either structural
elements in the protein’s ligand binding pocket or as a ligand-based filter based on SSRI structure.
A hSERT 3D pharmacophore for the S2 binding pocket that included an ionic / hydrogen bonding
feature between R104 (TM1) and E493 (TM10), a hydrogen bonding feature from K490, a
hydrophobic feature from Y107, and a hydrophobic feature within a subpocket defined by L99,
W103, and I179, previously termed the halogen binding pocket (Zhou et al., 2009; Manepalli et
al., 2011) Similarly, Kortagere used a structural pharmacophore comprised of an hydrophobic
feature at Y568, and hydrogen bonding features at D328, E494, and R564 (Kortagere et al., 2013).
Nolan et al. incorporated a minimalist structural pharmacophore with one hydrogen bonding
feature on D98, while Gabrielsen et al. built a pharmacophore based on desmethyl-(R)-fluoxetine
containing a positive ionizable feature, a hydrophobic feature, and an aromatic feature that was
utilized to filter the screening library before the docking calculations were completed (Gabrielsen
et al., 2014; Nolan et al., 2014).
An alternative approach is to quantitatively examine the relationship between the predicted
affinity from the docking evaluation with the known experimental binding data, which is the
approach taken by this study. A test set containing 24 compounds with known SERT affinity
ranging from low nM affinity (< -12 kcal) to mM affinity (-5 kcal), which allowed for correlation
testing to be completed to evaluate the performance of the software. MOE software was selected
to complete the present virtual screen due to its ability to easily add side chain flexibility, the
shorter computational time needed to complete the simulations, and general performance of the
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available scoring functions against the human SERT compared to Schrödinger and Autodock
software during initial benchmarking. The flexible docking protocol within MOE relies on the
selection of two scoring functions; the first responsible for the ligand’s initial placement within
the binding pocket; the second is responsible for rescoring the pose. Therefore, combinations of
the scoring functions in MOE (ASE, Affinity dG, Alpha HB, GBVI/WSA dG, and London dG)
were used to evaluate the test set against the experimental affinity using the Pearson correlation
test. The initial question examined if the two Na+ ions within the binding site impacted the scoring
of the test set. The Pearson coefficient for the simulations without ions ranged from 0.44 – 0.67
(R2 = 0.19 – 0.45) (Table 2.3). Completion of the simulations with the two Na+ ions revealed an
improvement of the Pearson correlation coefficient with the ASE-London dG combination
producing an R of 0.73 (R2 =0.54). The addition of sodium atoms within the binding pocket may
stabilize the OF conformation of SERT and allows it to accept ligands from the extracellular side
(Aggarwal and Mortensen, 2017).
With the desired scoring function combination identified for SERT, the next task was to
optimize the performance of the simulations before completion of the virtual screen. The docking
protocol was modified to include a structural pharmacophore applied to D98 similar to that used
in the Nolan et al. study, which resulted in Pearson, Spearman, and Kendall correlation coefficients
of 0.73, 0.79, and 0.58 respectively (Table 2.5). The Spearman coefficient is an additional
correlation test that is rank-order in nature, which may pick up relationships missed by the Pearson
coefficient. The ASE-London dG combination achieved a Spearman coefficient 0.79 in MOE
compared to alternative Autodock and Schrödinger Glide software that ranged from 0.61 to 0.69
in initial benchmarking. The advantages of MOE software were apparent when allowing for side
chain flexibility during the docking calculation. Autodock only allowed limited side chain
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flexibility that could not encompass the entire S1 binding site, and Glide software required too
much computational time to reasonably completed a virtual screen. The virtual screen targeting
the S1 site by Erol et al. only allowed for flexibility of five amino acids within the pocket (D98,
I172, Y176, F335, and S438) during the re-evaluation with GOLD docking software (Erol et al.,
2017). The structural pharmacophore was a filter used to eliminate compounds that lacked the
crucial D98 interaction necessary for binding of high affinity ligands, which filtered two
compounds of the test set (tranylcypromine and alprazolam) that display weak SERT binding
experimentally (Table 2.5). The resulting predicted affinity (S score) of the test set ranged from 8.3 to -16.3 (Table 2.5). The benchmarking screen was completed in with 8 of the 9 top compounds
scoring below -13.5 and 6 of the top 9 below -14. This gave assurances about the predictability of
the software to target SERT, as poorly binding compounds ranked lower, with only one compound
in the bottom 12 scoring below -13.5. One notable aspect was that citalopram constantly ranked
as the top compound with an S score around -16. This may be due to the fact that the citalopram
was originally co-crystalized within the binding pocket, although this should not be the case due
to the refinement with molecular dynamics allowing the apo binding pocket to relax.
With the virtual screening protocol validated, focus shifted to its utilization to identify
potential inhibitors (pharmacologically profiled in Chapter 3). The Maybridge HitDiscoverer
chemical library was chosen explicitly due to its recent curation at the time of the screen, the
commercial availability, and the relatively inexpensive cost. Commercial availability was a key
consideration due to the associated cost and time savings compared to traditional synthesis. The
Asinex, Chem-Bridge, ChemDiv, Enamine, Life Chemicals, Otavia, and ZINC chemical libraries
have been previously screened using SERT models (Manepalli et al., 2011; Gabrielsenet al., 2014;
Nolan et al., 2014; Erol et al., 2017). The structural coordinates of the HitDiscoverer library were
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rebuilt in 3-dimensions following the same protocol as the docking test set and contained 51,775
compounds.

The pharmacophore filtered 7,775 compounds while the remaining 44,000

compounds were scored and ranked. The first set of criteria to filter the compounds used the
Lipinski Rule of 5 - a set of parameters initially utilized by Pfizer to define drug like molecules in combination with predicted affinity (S score < - 17), yielding 415 compounds. The compounds
highest-ranked by predicted affinity were next filtered with S score filter to < -18, which retained
44 compounds. Rather than pick compounds by visual inspection alone, an analytical route was
chosen to identify the 10 compounds for purchase. Initially, compounds were sorted into groups
by properties such as the number of hydrogen bond donors and acceptors, but the criteria used to
filter the compounds displayed too much overlap to sufficiently separate the compounds. The 44
compounds were chemically fingerprinted using MayaChemTools scripts and ranked for their
chemical uniqueness using the Tanimoto coefficient. Each of 44 compounds was structurally
unique, and the 10 compounds with the lowest coefficient were selected for purchase.
Unfortunately, Compound 3 was discontinued by the manufacturer after the initial purchase,
preventing a thorough pharmacological analysis.
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Chapter 3: Pharmacological Analysis of the Candidate Compounds
Background
Approximations within the scoring functions enable the computational software to
complete virtual screens of large chemical libraries within feasible timeframes; unfortunately,
these estimates also increase the likelihood of favorably scoring compounds later found to lack
pharmacological activity (Huang et al., 2010).

Therefore, extensive validation of the

computational protocol is crucial to provide the best opportunity to identify viable candidate
compounds and filter out the unlikely ligands (Sliwoski et al., 2014). Following acquisition of the
candidate compounds either through synthesis or purchase, it is necessary to confirm the results of
the screen through pharmacological analysis. The initial pharmacology of potential SERT ligands
and inhibitors typically utilizes in vitro assays to determine if the candidate compounds bind to the
protein, inhibit intracellular transport of serotonin, or promote efflux of stored substrate (Tatsumi
et al., 1997; Nolan et al., 2014). Cell lines such as HEK-293 that are transfected to express SERT
are combined with radiolabeled ligands and inhibitors to probe the pharmacological activity of the
candidate compounds (Tatsumi et al., 1997; Nolan et al., 2014).
Determination of the candidate compound’s SERT binding affinity is measured through their
ability to displace radioligand inhibitors of SSRIs, or cocaine analogs such as RTI-55 that inhibit
SERT, DAT, and NET (Little et al., 1993; Tatsumi et al., 1997). An initial total binding assay at
a single concentration usually around 1-10 µM is typically used to establish candidates for full
concentration response curves with competitive binding assays. Inhibitor binding alone does not
indicate the ability to block transport of the endogenous substrate serotonin. Therefore, functional
assays are necessary to determine inhibition potency and efficacy.

Inhibition potential is

established by preincubating the candidate compound with SERT-bearing cells before addition of
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radiolabeled substrate, then measuring the ability of the compound to block transport of the
radioligand into the cell. Certain compounds such as 3,4-methylenedioxy-N-methylamphetamine
(MDMA; ecstasy) promote efflux, or reverse transport, of stored intracellular substrate (Sandtner
et al., 2016). The efflux assay is similar to the uptake assay except that the cells are preloaded
with radiolabeled substrate, and the candidate compound’s ability to block cellular release of the
stored radioligand is measured (Wall et al., 1995).
SERT Virtual Screens
Early SERT virtual screens focused on the allosteric binding pocket / S2 site, which was
thought to be the antidepressant binding site on LeuT
(Figure 3.1) (Singh et al., 2007; Zhou et al., 2009;
Grouleff et al., 2016).

The Surratt and Madura

laboratories were among the first by screening the ZINC
chemical library through the S2 binding site of a SERT
model (Manepalli et al., 2011). The pharmacophore
criteria returned 4097 compounds before using visual
inspection and predicted affinity to rank the top 68
compounds (Manepalli et al., 2011). Ten of the top
15 compounds were purchased for pharmacological
analysis. Initial binding was assessed at a 10 µM

Figure 3.1: LeuT S1 and S2 Occupied.
LeuT Crystal structure (teal; PDB id.
3GWU) with the antidepressant paroxetine
(yellow) bound within the S2 site above the
S1 site occupied by leucine (red).

concentration for the SERT, DAT, and NET proteins using a total binding assay against [125I]RTI-55, with compounds that significantly displace the radioligand further examined using
competition binding assays (Manepalli et al., 2011).

Compounds SM-10 and SM-11 were

determined to have micromolar binding affinity with Ki values of 38 and 17 µM (Manepalli et al.,
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2011). Additionally, none of the compounds inhibited [3H]-5HT uptake at a 10 µM concentration
(Manepalli et al., 2011). The Kortagere study also screened the S2 site identifying 10 compounds
for pharmacological evaluation using [3H]-5HT uptake and [3H]-5HT release assays (Kortagere et
al., 2013). One compound (ATM7) was characterized as an allosteric modulator that increased
5HT uptake and potentiated 5HT efflux by 3,4-methylenedioxy-N-methylamphetamine (MDMA;
ecstasy) (Kortagere et al., 2013). ATM7 was hypothesized to work through stabilizing the OF
conformation of SERT (Kortagere et al., 2013).
A fundamental shift in the understanding of binding occurred with the crystallization
dDAT structures with inhibitors and substrates within
the S1 or orthosteric binding pocket (Figure 3.2)
(Penmatsa et al., 2013). The first screen against the S1
pocket was completed by Gabrielson et al. using the
Asinex, ChemBridge, ChemDiv, Enamine, and Life
Chemical libraries (Gabrielsen et al., 2014). Filtering
by the Lipinski Rule of 5, Verber (oral bioavailability),
basic property (pKa between 3 and 11.5), ADMET
properties,

and

a

ligand-based

pharmacophore

(positive ionic charge, aromatic feature, and
hydrophobic portion) left 2293 compounds to be
flexibly docked using a previously developed 4D

Figure 3.2: dDAT S1 Occupied. dDAT
Crystal Structure (blue; PDB id. 4M48)
with
the
tricyclic
antidepressant
amitriptyline (yellow) bound within the S1
binding pocket.

approach (Gabrielsen et al., 2012; Gabrielsen et al., 2014). Two-hundred and two compounds
were purchased for pharmacological analysis at SERT. A total binding assay against [3H]citalopram identified 23 compounds for competition binding curves with an additional 23
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compound chosen to develop structure activity relationships.

In all, 24 compounds were

characterized with a Ki below 1000 nM with 13 additional compounds having a Ki between 1000
nM to 3100 nM (Gabrielsen et al., 2014). Later screening of analogs identified an additional 22
compounds with a Ki under 1000 nM (Gabrielsen et al., 2014).
The second SERT virtual screen published by the Surrat and Madura laboratories screened
the PubChem database within the S1 binding pocket of the SERT model (Nolan et al., 2014). The
13,378 compounds ranked compounds were visually inspected based on pharmacophore fit (D98),
chemical complexity, and synthetic viability, which identified 49 compounds of interest (Nolan
et al., 2014). Nineteen compounds were commercially available and pharmacologically evaluated
to determine binding affinity (Ki) for the MATs (SERT, DAT, and NET) and inhibition efficacy
(IC50) for SERT (Nolan et al., 2014). Four compounds (TN-1, TN-5, TN-6, and TN-13) were
selected for full competition binding curves for SERT with Ki values ranging from 668 to >20,000
nM and IC50 values ranging from 3845 to >20,000 nM from the [3H]-5HT uptake inhibition assay
(Nolan et al., 2014).
Following publication of the human SERT crystal structures, only one study virtual screen
utilized the structures (PDB id. 5I6X and 5I73) and screened the Otava Chemicals Drug Like Green
chemical library through both the S1 and S2 pockets (Erol et al., 2017). Glide software was
initially used and compounds scored within -2 kcal of the top ranked compound were kept leaving
9163 for the S1 and 999 for S2 (Erol et al., 2017). Consensus scoring by docking algorithms
within the Schrödinger software suite identified 3 compounds for S1 (compounds 160234, 159166,
69419) and 1 compound for S2 (compound 93507) (Erol et al., 2017). Molecular dynamics
simulations and free energy calculations using MM/GBSA within Schrödinger software were used
to computationally validate these compounds as SERT inhibitors (Erol et al., 2017). Although this
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is technically the first virtual screen utilizing the human SERT crystal structures, the lack of
pharmacological validation hinders the final conclusions made by the study. The prior 4 SERT
virtual screens pharmacologically profiled 241 compounds with only 44 compounds displaying
moderate binding affinity or modulated serotonin transport (Manepalli et al., 2011; Kortagere et
al., 2013; Gabrielsen et al., 2014; Nolan et al., 2014). This hit rate of 18% highlights the necessity
of pharmacological evaluation to validate the computational approach.
Pharmacological Approach
Chapter 2 of this thesis detailed the computational approach taken to identify 10 candidate
compounds for pharmacological profiling. While all 10 compounds were purchased from ThermoFisher, only 9 were able to be fulfilled by the manufacturer and evaluated. A HEK-293 cell line
that stably expressed SERT was acquired to determine binding, inhibition efficacy, and release
potential of the candidate compounds. A total binding assay using 10 µM of candidate compound
against [3H]-citalopram was completed to identify compounds that bound to SERT.

One

compound displaced the radioligand comparable to the positive control paroxetine and was chosen
for full concentration response curves. Additionally, each compound was tested at 10 µM for
inhibition potential and release potential using [3H]-serotonin. Two compounds blocked serotonin
below 50% of vehicle and concentration response curves were completed.
promoted the release of stored substrate in the release assays.
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No compound

Methodology
Candidate Compound Preparation. The nine candidate compounds identified from the virtual
screen were purchased from Thermo Fisher as part of the Maybridge chemical collection. To
prepare the compounds for pharmacological testing, the 5 mg of candidate compounds were
suspended in DMSO under sterile conditions to achieve 10 mM concentration stocks.

Cell Culture. To pharmacologically classify the candidate compounds against SERT using in vitro
experiments, a Human Embryonic Kidney – 293 (HEK293) stably transfected to express the
human SERT (HEK293-SERT) was acquired as a generous gift from Dr. Randy D. Blakely
(Florida Atlantic University, Boca Raton, FL). The initial culturing of the HEK293-SERT cells
was completed by thawing the cryovial by hand and resuspending the cells with 10 ml of media in
a 15 ml tube, which was centrifuged at 10,000 rpm for 10 minutes to separate the freezing media
(10% DMEM:F-12, 10% DMSO, 80% FBS) from the cells. Following the aspiration of the liquid
within the 15 ml tube, the pellet of cells was resuspended with 12 ml of media (DMEM:F-12, 10%
FBS, 1% Pen/Strep) and cultured in a medium sized flask (T75) at 37o C and 5% CO2. The
HEK293-hSERT cell line was cultured under the conditions as described (Tatsumi et al., 1997)
until confluence. Cells were then scraped into 15 ml screw tubes and lightly pelleted by
centrifugation (500 rpm) for 10 minutes. The media was aspirated, and the remaining pellet was
layered with medium before freezing at -20C.

Total Binding Assay. To assess whether the candidate compounds bound to SERT, radioligand
binding assays were performed using [3H]-citalopram. To assess for specific binding, saturating
(10µM) concentrations of sertraline was added to parallel sets of tubes. To calculate the total,
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specific and non-specific binding of the 9 candidate compounds, the positive control (sertraline)
and the vehicle (DMSO), 4 vials per compound were collected (2 vials for total binding and 2 vials
for specific) in 24 well racks. 20 µl of buffer (50 mM TRIS) was added to each vial (40 µl for the
total binding), followed by the addition of 20 µl of the cold compound to achieve a final
concentration of 10 µM. 20 µl of the hot radioligand [3H]-citalopram (Perkin Elmer, citalopram,
[N-METHYL-3H], product # NET1039250UC) was added using a 1/42 dilution to achieve a final
concentration of 16 nM. Two hundred µl of the membrane preparations were then added to each
vial, which was calculated to contain 1.6 mg of protein per ml or 320 µg of protein per vial. Each
vial was washed three times utilizing a 0.5% PEI soaked filter with a Brandel Harvester. The filter
for each sample was collected in a scintillation vial with 5 ml of fluid and counted with a
scintillation counter. The total, specific and non-specific binding was then normalized to the
amount of protein present in the membrane preparation.

Competition Binding Assay. The candidate compounds determined from the total [3H]-citalopram
binding assays that demonstrated any specific binding were subjected to further analysis using
competition binding assays using [3H]-citalopram. Increasing concentration of the candidate
compounds were run in the presence of a constant concentration of [3H]-citalopram (16 nM). This
was to calculate affinity of the candidate compounds to SERT (Ki). For each candidate compound
tested and the positive control (sertraline), a rack consisting of 24 vials was used that contained 6
vials for total binding and duplicate vials for the drug concentrations ranging from 1 pM to 100
mM. Once the rack setup was complete, 20 µl of buffer (50 mM TRIS) was added to each vial
with 40 µl added to the total binding vials. This was followed by the addition of the cold drug in
20 µl amounts to achieve the desired final concentration. The hot radioligand [3H]-citalopram was
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added in 20 µl amounts to each vial using a 1/42 dilution to get to a final concentration of 16 nM.
The cell lysates were next added in 200 µl amounts followed by vertexing and incubated at room
temperature for 1 hour. A Brandel harvester with 0.5% PEI soaked filters was used to filter the 24
vials, which were washed 3 times. The filter for each sample was then collected within a
scintillation vial with 5 ml of fluid and counted with a scintillation counter. Data points were fit
by non-linear regression analysis and the best fit was determined through least squares fit.

Total [3H]-Serotonin Uptake Inhibition. To assess whether or not the candidate compounds
inhibited at all 3H-serotonin uptake, initial screens were performed using 10 µM candidate
compounds. This was conducted to identify any candidate compounds that demonstrated 50% or
greater inhibition. The HEK293-SERT cells were cultured on 24 well plates precoated with polyd lysine (PDL) over night at 37o C at 5% CO2. The media within each well was aspirated with a
vacuum pump and washed twice with 1 ml of KRH buffer. KRH buffer (0.5 ml) was added to
each well followed by the addition of 0.5 µl of the 10 mM candidate compound stock completed
in duplicate. The vehicle (DMSO; wells 1 and 2), positive control (citalopram; wells 3 and 4), and
the basal response (no treatment; wells 23 and 24) were measured in duplicate. After the addition
of the candidate compound or control, each well was incubated at room temperature for ten
minutes. The [3H]-serotonin stock was prepared by addition of KRH buffer in a 1:1 ration (13 µl
serotonin to 13 µl KRH buffer). Following the ten-minute drug incubation, 1 µl of [3H]-serotonin
mixture was added to each well for 5 minutes before aspiration and subsequently washed twice
with KRH buffer to end the uptake. To assess the concentration of the [3H]-serotonin within the
cells, 1 ml of SDS was added to each well and shaken at room temperature for 1 hour to break
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open the cells, which were further scraped and transferred to scintillation vials with 5 ml of
scintillation fluid and counted with scintillation counter.

Concentration Response [3H]-Serotonin Uptake Inhibition. Candidates that were found to inhibit
[3H]-5HT uptake by 50% or greater were subjected to further analysis by constructing
concentration response curves using concentrations of compounds between 100 pM to 1 µM. This
was completed to calculate potency and efficacy of compounds which were then compared to the
vehicle (DMSO) and the positive control Citalopram. Data points were fit by non-linear regression
analysis using variable slopes. Potency, IC50, or efficacy were calculated.

[3H]-Serotonin Release Assay. To assess if any of the candidate compounds promoted the release
of [3H]-5HT (Perkin Elmer, 5-hydroxy tryptamine, [3H], product # NET1167250UC) from within
the cell, a serotonin release assay was completed using [3H]-5HT. The candidate compounds,
vehicle (DMSO), positive control (citalopram), and basal response (no treatment) were measured
in triplicate for this assay. The HEK293-SERT cells were cultured in PDL coated 24 well plates
overnight at 37oC with 5% CO2 and 100% humidity, which was aspirated and washed twice with
KRH buffer. The [3H]-5HT stock mixture for this experiment was created using a 1:1 ratio of
radioligand to KRH buffer (15 µl [3H]-5HT with 15 µl KRH buffer). Each well received 0.5 ml
of KRH buffer followed by the addition of 1 µl of [3H]-5HT and incubated at room temperature
for 30 minutes. Each well was aspirated of its media and washed with 0.5 ml of KRH buffer both
of which were collected in a scintillation vial (count 1; load). The plates were reloaded with 0.5
ml of KRH buffer and 0.5 µl of the 10 mM candidate compound stocks were added to each well
and incubated at room temperature for 30 minutes. The media was then aspirated, and each well

55

was washed with 0.5 ml of KRH buffer, which was collected in scintillation vials and counted
(count 2; release). To count the contents of the cells, 1 ml of SDS buffer was added to each well
and the plates were shaken at room temperature for 1 hour. The cells were scrapped and collected
in scintillation vials (count 3; load). The uptake efficiency of the experiment was calculated by
dividing the total (count 1) by the load (count 3). To examine the release of [3H]-5HT, the release
(count 2) normalized by the load (count 3) as release / load. The released [3H]-5HT was also
examined with its relationship to the initial amount of [3H]-5HT added by dividing the release
(count 2) by the total (count 1).

GPCR Screen from the PDSP. To determine the potential selectivity of the candidate compounds,
the Mark Roth lab at the University of North Carolina completed a functional screen against a
panel of GPCRs containing over 300 receptors including the serotonin, dopamine, and
norepinephrine receptors (full list of receptors found in Appendix Tables A.2-A.11). The PDSP
used a PRESTO-TANGO assay, which is a modified arrestin assay designed to promote
luminescence upon activation of the GPCR (Kroeze et al., 2015). The candidate compounds were
tested at a 3 µM final concentration completed with quadruplicate with the dopamine d2 agonist
quinpirole at 400 nM concentration serving as the positive control. The complete results can be
found in Appendix Tables A.2 – A.11.
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Results

Figure 3.3: Total Binding Analyses of Candidate Compounds to SERT. Candidate
compounds (1, 2, 4, 5, 6, 7, 8, 9, 10) were screened for their ability to bind to SERT using
[3H]-citalopram [16 nM]. Data in (A) depict total, non-specific and specific binding of [3H]citalopram to SERT normalized by total protein while those depicted in (B) represent specific
binding only. Parallel sets of experiments using the positive SSRI control, sertaline (10 µM)
and the vehicle, DMSO were run. Each bar graph represents the mean +/- (SD) of preformed
in duplicate.
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A. Composite Binding Curve

B. Assay 1

C. Assay 2

Figure 3.4: Competition of Sertraline for [3H]-Citalopram Binding to SERT. The
affinity of sertraline (1pM-100mM) for SERT was assessed by competition binding using
the radioligand [3H]-citalopram. A composite binding curve (A) was constructed from
individual curves shown in (B) and (C). Individual (B, C) or composite (A) affinity (IC50,
Ki) values were derived by GraphPad Prism non-linear regression analyses least squares
fit. Each data point represents the mean +/- (SD) of two independent experiments
performed in duplicate for (A) or one experiment performed in duplicate (B, C).
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A. Composite

B. Assay 1

C. Assay 2

D. Assay 3

Figure 3.5: Competition of Compound 4 for [3H]-Citalopram Binding to SERT. The
affinity of compound 4 (1pM-100mM) for SERT was assessed by competition binding using
the radioligand [3H]-citalopram. A composite binding curve (A) was constructed from
individual curves shown in (B), (C), and (D). Individual (B, C, D) or composite (A) affinity
(IC50) values were derived by GraphPad Prism non-linear regression analyses least squares
fit. Each data point represents the mean of three independent experiments performed in
duplicate for (A) or one experiment performed in duplicate (B, C, D).
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Figure 3.6 Single Point Substrate Uptake Inhibition of Candidate Compounds to SERT.
Initial screen of hit compounds to inhibit [3H]-serotonin transport with HEK-293 cells stably
expressing the SERT protein. The cells were preincubated with 10 µM concentration of each
compound, citalopram, vehicle (DMSO), and basal. Data represents the mean +/- (SD) of 6
independent assays performed in duplicate. Active compounds were defined as inhibiting
greater than 50% uptake of the vehicle.
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Citalopram (Positive Control)

Compound 1

Compound 4

Figure 3.7: Concentration Response Substrate Uptake Inhibition with Citalopram,
Compound 1, and Compound 4 for SERT. Compounds 1 and 4 were determined to be
active inhibitors of the SERT protein (Figure 3.6). Full dose response curves (100 µM to
1 pM) were completed with compounds 1, 4, and citalopram (positive control). Data is
presented as the mean expressed as percent vehicle (DMSO treatment) or percent basal
(no treatment) +/- (SD) of 3-4 independent assays performed in duplicate.
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Figure 3.8: Release Assay with the 9 Compounds. To assess the ability to of the hit
compounds to export [3H]-serotonin from HEK-293 cells stably expressing the SERT
protein. Cells were preloaded with [3H]-serotonin for 30 minutes before incubation with
hit compounds, citalopram, vehicle (DMSO), and basal response (no treatment).
Experimental compounds and citalopram were assessed at 10 µM concentration. Media
was collected and counted after 30-minute addition of [3H]-serotonin (total), after drug
treatment (release), and within the cell (load). Assay represents the mean +/- (SD)
performed in triplicate.

62

Table 3.1 Comparison Between Virtual Screening Analysis and Pharmacology.
Compounds are sorted by predicted binding affinity to compare the results of the Total Binding
assay and the [3HT]-5HT uptake assay. Compounds identified as inhibitors of SERT are
highlighted in yellow. The SSRI controls are listed at the bottom for each assay.
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A.

B.

C.

D.

Figure 3.9: Binding Interactions Between Compound 1 and the S1 Binding
Pocket of SERT. Two vantage points of compound 1 in the space filling model is
shown in panels A and B, which the overall position of the compound within SERT is
shown in panel C. To clarify the binding interactions shown in A and B, a 2D
representation is shown in panel D.
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A.

B.

C.

D.

Figure 3.10: Binding Interactions Between Compound 4 and the S1 Binding Pocket of
SERT. Two vantage points of compound 4 in the space filling model is shown in panels A
and B, which the overall position of the compound within SERT is shown in panel C. To
clarify the binding interactions shown in A and B, a 2D representation is shown in panel D.
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Results
Total Binding Assay
To establish if any of the 9 experimental compounds bound to the SERT protein, a total binding
assay was completed utilizing [3H]-citalopram. The total binding (T), non-specific binding (NS)
and specific binding (S) values for each experimental compound were recorded along with the
positive control sertraline and the vehicle DMSO, which were normalized to mg of protein used
in the assay (Figure 3.3A) and plotted with the isolated specific binding (Figure 3.3B). Compound
4 (222.8 fmol / mg protein) showed comparable binding to sertraline (179.2 fmol / mg protein).
Compounds 1 (19.4 fmol / mg protein), 6 (69.5 fmol / mg protein), 8 (46.4 fmol / mg protein), and
10 (42.1fmol / mg protein) showed limited specific binding while compounds 2, 5, 7, and 9 had
negligible specific binding.
Competition Binding Assays
To further define the binding profile of the experimental compounds that displayed specific
binding in the total binding assay (Compounds 1, 4, 6, 8, and 10), competitive binding assays were
completed using concentrations of the candidate compounds ranging from 1 pM to 100 mM against
16 nM of [3H]-citalopram. Assays for compounds 1, 6, 8, and 10 were completed but displayed
no convergence. IC50 values (high and low) for calculated as a composite graph (IC50 high of 0.9
nM and an IC50 low of 313 mM) and as calculated from averaged individual experiments for
compound 4 (0.5 nM (range 250 pm to 1.07 nM) and IC50 low of 0.4 mM (range 90 µM to 2.6
mM) (Figure 3.5). The positive control sertraline was reported to have a Ki value of 0.35 nM
(Figure 3.4).
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Total [3H]-Serotonin Uptake Inhibition
To determine if the novel compounds are SERT inhibitors, a single concentration (10 µM) of
compounds 1 through 10 was administered to stably transfected SERT cell line before addition of
[3H]-5HT to examine if the novel compounds blocked the transport of the serotonin. Inhibitors
are defined as compounds blocking at least 50% of [3H]-5HT compared to vehicle. Citalopram
was used as a positive control and resulted in 2% of vehicle (98% inhibition of uptake).
Compounds 1 (33% of vehicle) and compound 4 (19% of vehicle) were classified as inhibitors,
while compound 5 was a borderline candidate (57% of vehicle) due to the standard error falling
below the 50% threshold (Figure 3.6).
Concentration Response [3H]-Serotonin Uptake Inhibition
To establish the potency of compounds 1 and 4 as inhibitors of SERT, concentration response
curves were conducted using 1pM to 10 mM concentrations (Figure 3.7). The positive control
citalopram was chosen in an IC50 of 1.1 nM compared to vehicle and 0.4 nM compared to basal.
Compound 1 resulted in an IC50 of 6.6 µM compared to vehicle (8.0 µM compared to basal
response), while compound 4 had an IC50 of 3.4 µM compared to vehicle (4 µM compared to basal
response).
[3H]-Serotonin Release Assay
To assess the novel compounds ability to release (export) [3H]-5HT from within the HEK-293
cells, the cells were preloaded with [3H]-5HT for thirty minutes before incubation with compounds
1 through 10. The media was collected for counting after the 30-minute addition of [3H]-5HT
(total), after drug treatment (release), and stored within the cell (load). To assess the uptake
efficiency (load (5HT within the cell) divided by total 5HT added), which was under 3% for the 9

67

experimental compounds, positive control (citalopram), basal (no treatment) and vehicle (DMSO)
groups. To assess the release of [3H]-5HT, the release measurement was divided by the load and
showed no statistical difference between the 9 experimental compounds and citalopram compared
to the vehicle DMSO group. To assess if the total [3H]-5HT initially added affected the released
amount, the release measurement was divided by the total measurement. In all groups, the release
/ total was under 1.5% with no statistical differences compared to vehicle (Figure 3.8).
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Discussion
The work within this doctoral thesis was completed with the goal of using computational
modeling to rationally discover novel inhibitors of hSERT. The computational approach, detailed
in Chapter 2, targeted the orthosteric binding pocket (S1) of hSERT using MOE software. The
virtual screen analytically identified 10 candidate compounds with 9 compounds commercially
available for purchase from Thermo-Fisher. The initial pharmacological analysis was completed
using human embryonic kidney cells – 293 (HEK-293) that stably expressed hSERT, which was
generously donated by Dr. Randy D. Blakely of the Florida Atlantic University, and examined
binding, efficacy as inhibitors, and release potential. In addition, the agonist functional data was
generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening
Program, Contract # HHSN-271-2018-00023-C (NIMH PDSP). The NIMH PDSP is Directed
by Bryan L. Roth at the University of North Carolina at Chapel Hill and Project Officer Jamie
Driscoll at NIMH, Bethesda MD, USA. The PDSP screened 8 of the 9 candidate compounds
against a wide panel of GPCRs including the serotonin, dopamine and adrenergic receptors (see
Appendix Tables A2-A11).
In order to determine if the candidate compounds bind to hSERT, a total binding assay was
completed at an initial concentration of 10 µM of compounds 1 through 10 and the positive control
sertraline against [3H]-citalopram (Figure 3.3). This assay identified that 5 of the 9 compounds
had specific binding to hSERT although only compound 4 (222.8 fmol / mg protein) had
comparable specific binding compared to sertraline (179.2 fmol / mg protein). Compounds 1 (19.4
fmol / mg protein), compound 6 (69.5 fmol / mg protein), compound 8 (46.4 fmol / mg protein),
and 10 (42.1 fmol / mg protein) were chosen for further evaluation with competitive binding assays
along with compound 4, while compounds 2, 5, 7, and 9 were disregarded due to negligible specific
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binding. Competition binding assays were completed using a range of concentrations from 1pM100mM with sertraline as the positive control. The competition for compound 4 was analyzed as
a composite graph (Figure 3.5A) comprised of three individual experiments (Figure 3.5 B, C, and
D), and as an averaged value derived from the individual experiments with both situations having
a 2-site fit. Data for the composite was recorded as Ki values (1 nM high and 1 µM) and IC50
values (0.9 nM high and 313 mM low), while IC50 values were reported for the averaged values
(0.5 nM high and 0.4 mM low). Compounds 1, 6, 8, and 10 were characterized with competition
binding assays but the graphs were determined to be non-convergent. The positive control
sertraline was also analyzed as a composite graph (Figure 3.4A) with a Ki of 0.35 nM and
individual graphs (Figure 3.4B and C). Both the total binding and competitive binding assays were
hindered by issues with high non-specific binding, which could be due to low receptor expression
and the potential of the radioligand being “sticky”. In addition, the competitive binding assays
were impacted by the concentration of [3H]-citalopram used in the experiments. A concentration
of 16 nM was chosen due to being roughly 80% of the BMax value on recommendation by advisors
but it was much higher concentration than reported in the literature. Compounds 1, 6, 8, and 10
were unable to displace the radioligand at that concentration, which combined with the high nonspecific bindings led to no convergence when examining their competition binding curves.
The primary goal of this study was to identify inhibitors of hSERT through computational
modeling. Therefore, the efficacy the candidate compounds were determined using a substrate
uptake inhibition assay that measured each compound’s ability to inhibit the transport of [3H]-5HT
into the cell. The 9 compounds along with the positive control citalopram were initially tested at
a 10 µM concentration with inhibition being defined as a greater than 50% reduction of internal
[3H]-5HT compared to the vehicle DMSO (Figure 3.6). This criterion established compounds 1
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(33% of vehicle) and 4 (19% of vehicle) as hSERT inhibitors and candidates for full concentration
response curves. The efficacy of the SSRI citalopram was evident with the almost complete
blockage of [3H]-5HT at 3% of uptake compared to vehicle. Compound 5 (56% of vehicle) was a
borderline candidate for further examination due to its proximity to the 50% mark. When full
concentration response curves were completed, compound 4 (IC50 = 3.4 µM compared to vehicle)
was found to be more potent than compound 1 (IC50 = 6.6 µM compared to vehicle) (Figure 3.7)
matching the results of the single point assay. The positive control citalopram was found to have
an IC50 of 1.1 nM compared to vehicle. A concentration response curve for compound 5 was
initially examined but quickly abandoned when the 10 µM concentrations were found to above the
50% of vehicle mark to conserve limited [3H]-5HT supplies.
A [3H]-5HT release assay was the last pharmacological assay completed, which was used
to determine if the candidate compounds act as “releasers” through efflux or reverse transport.
Examples of releasers at the MATs include the amphetamine family of compounds most notably
working through DAT. The [3H]-5HT release assay is essentially the reverse of the [3H]-5HT
uptake inhibition assay with the radioligand being preloaded into the cells before the addition of
the candidate compounds. The inhibitor citalopram was used as a positive control due to the lack
of a releaser to use with this assay. To determine if the candidate compounds caused efflux, the
amount of [3H]-5HT released was normalized to the amount of [3H]-5HT loaded into the cell
(release / load; Figure 3.8B), which showed no statistical difference between the candidate
compounds compared to vehicle. The release / load was comparable to the amount of baseline
efflux seen in other studies. To determine if the initial concentration of [3H]-5HT added affected
release, uptake efficiency (load / total) was assessed at under 3% for all candidate compounds and
controls with no statistical difference compared to vehicle. Additionally, the release / total for
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each compound was at under 1.5% for all compounds with no statistical difference compared to
vehicle. Therefore, none of the 9 candidate compounds were determined to be releasers through
SERT.
In total, this study targeted the S1 binding pocket of SERT and identified 10 candidate
compounds for pharmacological analysis. Of the 9 compounds acquired, compound 1 and
compound 4 were characterized as inhibitors of SERT with 6.6 µM and 3.4 µM IC50 values
determined by the [3H]-5HT uptake inhibition assay (Figure 3.7). To the authors knowledge, there
have been 5 virtual screens targeting SERT reported in the literature with 4 studies that utilized
LeuT based homology models and completed pharmacological analysis of the identified
compounds. The lone study that utilized the hSERT crystal structure did not complete any
pharmacology associated with the study. The results of the 5 studies along with the data from this
study is summarized in Table 3.2. In comparison, the first virtual screen (Manepalli et at., 2011)
targeted the S2 site and identified two SERT ligands with 17 µM (compound SM-11) and 38 µM
(compound SM-10) Ki values but were unable to block [3H]-serotonin transport in uptake
inhibition assay at 10 µM concentration (Manepalli et al., 2011). A sister study from the same lab
screening the DAT S2 binding pocket identified one compound (MI-17) that was selective towards
SERT with a 284 nM Ki value over DAT and NET (Nolan et al., 2011). MI-17 was developed
into DJLDU-3-79 through molecular hybridization improving its binding affinity (Ki value) to 37
nM and its [3H]-5HT uptake inhibition potency to 441 nM from 1167 nM (MI-17) (Nolan et al.,
2011). One compound (ATM7) from the Kortagere et. al. was established as an allosteric
modulator of SERT that increased [3H]-5HT uptake and potentiated [3H]-5HT efflux elicited by
3,4-methylenedioxy-N-methylamphetamine (MDMA; ecstasy) through stabilizing an OF
conformation of SERT (Kortagere et al., 2013).

72

Table 3.2: Comparison of Pharmacology from SERT Virtual Screens. Each study is
summarized by model used, site targeted, number of compounds tested, pharmacological assays
used, and by major findings.

The publication of the LeuBAT and dDAT structures altered the focus of antidepressant
binding from S2 to S1 (Gabrielsen et al., 2014; Nolan et al., 2014). Gabrielson et al. examined
202 identified compounds for SERT binding and characterized 37 compounds with having a Ki <
3100 nM (Gabrielsen et al., 2014).

The second S1 screen focused on 19 compounds for

pharmacological analysis, which characterized 4 compounds with Ki values ranging 668 to
>20,000 nM and IC50 values ranging from 3845 to >20,000 nM (Nolan et al., 2014). This is
comparable to the 2 compounds identified within this virtual screen that have IC50 values of 3400
nM (compound 4) and 6600 nM (compound 1) (Figure 3.7).
After the internal pharmacological analysis was completed, the 9 candidate compounds
were evaluated using the NIMH’s PDSP service through the Bryon Roth lab at the University of
North Carolina. A functional screen was chosen against a wide panel of over 300 GPCRs including
the serotonin, dopamine, norepinephrine, adrenergic, and opiate receptors (see Appendix Table A3
for a complete list of screened receptors). This was completed using a parallel receptor-ome
expression and screening via transcriptional output – transcriptional activation following arrestin
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translocation (PRESTO-TANGO) assay, which is a modified β-arrestin recruitment assay that
links receptor activation to the promotion of a transcription factor for luminescence (Kroeze et al.,
2015). The PDSP examined 8 of the 9 submitted compounds at a concentration of 3 µM (Appendix
Tables A3-11) while the dopamine d2 receptor agonist quinpirole (400 nM concentration) served
as the positive control. Compound 8 was displayed 47% activation of the atypical chemokine
receptor 3 (CXCR7), which is structurally similar to the chemokine receptors but lack G-protein
recruitment upon activation (Ulvmar et al., 2011). Originally an orphan receptor, CXCL11 and
CXCL12 were identified as ligands with the receptor proposed to promote their sequestration
(Ulvmar et al., 2011). Recent studies have suggested that the atypical chemokine receptor 3 is an
atypical opiate receptor that binds many of the endogenous opiate peptides and prevents their
activation of the classical opiate receptors (Meyrath et al., 2020). No other receptor within in
panel displayed greater than 7% activation with any of the 8 experimental compounds screened by
the PDSP although this does not preclude any of the compounds from acting in an antagonistic
function. The PDSP Ki database, which catalogs the results of binding experiments, determined
that the SSRIs bind to other receptors than the MATs. Receptors with a Ki < 5 µM include the
5HT2A (fluoxetine, sertraline), the 5HT2B (fluoxetine), 5HT2C (citalopram, fluoxetine, sertraline),
alpha1 adrenergic (citalopram, fluoxetine, paroxetine, sertraline), alpha2 adrenergic (paroxetine,
sertraline), muscarinic acetylcholine M1 (citalopram, fluoxetine, paroxetine, sertraline), M2
(fluoxetine), M3 (fluoxetine), M4 (fluoxetine), M5(citalopram), histamine H1 (citalopram,
fluoxetine), and sigma 1 receptors (sertraline) (Ki Database; (Roth et al., 2000)). Activation of
5HT2 receptors within the brain are thought to contribute to many of the adverse effects of the
SSRIs including anxiety, insomnia, irritability, while receptors within the spinal cord contribute to
sexual dysfunction (Clayton et al., 2014). Gastro intestinal issues are thought to be due to
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activation of 5HT3 receptors (Browning, 2015). The SSRI fluoxetine is a 5HT2C antagonist (Ni
and Miledi, 1997). The results of the PDSP screen suggest that the two identified SERT inhibitors
(compound 1 and 4) may display an alternative side effect profile due to their lack of activation of
any GPCR within the panel. Although the serotonin receptors could still be activated by the
inhibition of SERT by these compounds. The results of the 9 candidate compounds against the
DAT and NET proteins are still awaiting analysis from the PDSP.
With the initial pharmacology completed, comparisons between the molecular modeling
completed in chapter 2 can begin to be compared to the total binding assay and the substrate uptake
inhibition assay that tested each of the candidate compounds at 10 µM concentration (Table 3.1).
Each candidate compound was sorted by the predicted affinity (S score), which ranked 1
compound scored in the -20s, 5 compounds in the -19s, and 4 compounds in the -18s. The first
interesting observation is that compound 4 was ranked the highest in predicted affinity (S score =
-20.2), total binding assay (specific binding = 222.8 fmol / mg protein), and [3H]-5HT uptake
inhibition (19.2 % of vehicle). The second highest ranked compound by the modeling is compound
3, which was discontinued by Thermo-Fisher after the purchasing for this study was completed.
Compound 1 was the third highest ranked compound by modeling (S score = -19.5) and was ranked
second in the [3H]-5HT uptake inhibition (33.8 % of vehicle). While the results of compound 1
and 4 were favorably ranked in comparison, it should be reminded that each of the ten compounds
were chosen in part due to their high predicted affinity ranking while weak binders in the
benchmarking study were ranked with an S score under -13. Nonetheless, the data demonstrates
that the virtual screen successfully identified 2 inhibitors of SERT in an analytically driven
process.
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Computational modeling can be used to provide insight into the differences between
compound 1 and 4. Examination of the molecular interactions of compound 1 revealed that the
chlorobenzene sits near the opening of the binding pocket forming an aromatic / hydrophobic
interaction with F335, which is considered one of the external gating residues for SERT, with the

Figure 3.11: Overlay of Compound 1 and Compound 4 within the S1 Binding Pocket.
(Panel A). The sulfur atom on compound 1 (magenta) forms a hydrogen bond with D98
separated by 3.81Å (Panel B). In comparison, the amine group on compound 4 (teal) forms
an ionic interaction between D98 at 2.53Å (Panel C), which is most likely responsible for
compound 4’s greater potency.
chlorine atom exposed to the vestibule (Figure 3.9). Compound 1 forms hydrogen bonds with
D98, N101, and T497. The second chlorobenzene group sits within a hydrophobic pocket near
Y95, Y176, F341, G498, and V501. Compound 4 adopts a strikingly similar pose within the
binding site compared to compound 1 (Figure 3.10). The benzene ring is partly exposed to the
vestibule and forms a non-polar interaction with R104 (Figure 3.10). An important difference
between the compounds is that compound 4 contains a protonated amine that forms an ionic
interaction with D98. This can be more clearly seen in the distance between D98 with compound
1 (3.81 Å; Figure 3.11B) and compound 4 (2.53 Å; Figure 3.11C). This is most likely why
compound 4 is a more potent inhibitor of SERT over compound 1. In comparison, the amine
groups on the SSRIs citalopram and paroxetine are 4.1 Å and 3.1 Å away from D98 respectively,
which was suggested as the reason why paroxetine has greater binding affinity over citalopram
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(Coleman et al., 2016). The benzodioxol group sits
within a hydrophobic pocket surrounded by Y95,
I172, F341, V343, and V501 similarly to the
chlorobenzene group seen in compound 1 (Figure
3.10). It should be noted that both compound 1 and
4 sit higher up within the binding pocket compared to
the crystalized SSRIs. Figure 3.12 shows and overlap
of compound 4 (teal) with citalopram (yellow) from
the PDB id. 5I73.

The fluorophenol group on

citalopram sits deeper within the S1 binding pocket
surrounded by A169, I172, A173, Y175, and L443. The

Figure 3.12: Comparison Between
Compound 4 with Citalopram.
Compound 4 (teal) sits higher within
the binding pocket compared to
citalopram (yellow).

computational modeling provides some insight into the two inhibitors identified by the virtual
screen.
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Chapter 4: Strengths and Limitations
Strengths
The computational approach utilized for this study thoroughly examined the performance of the
docking software against SERT with benchmarking using a test set of known ligands. This
provided the best opportunity to identify potential inhibitors and establish confidence that the
software would filter / rank unfavorably unlikely compounds. Additionally, this study utilized the
the S1 binding pocket of the hSERT crystal structure rather than a LeuT based model, which was
utilized in the four virtual screens that were validated with pharmacological analysis. Nine
compounds were purchased and evaluated for binding, inhibition, and release potential with 2
compounds (compounds 1 and 4) established as SERT inhibitors with low µM IC50 values while
the PDSP results concluded that the compounds displayed selectivity by not activating any of the
serotonin, dopamine or norepinephrine receptors during their GPCR functional screen. In total,
this study had a 22% hit rate (2 / 9) compared to the accumulated 18% (44 / 251) of the prior 4
virtual screens. The last consideration is the cost benefit of the study with the overall cost of each
compound purchased averaging $80, which made the entire study a reasonable endeavor for an
academic research lab.
Weaknesses
Many of the limitations of the study involve technical limitations of the pharmacological assays.
The first being a high incidence of non-specific binding within the total binding and competition
binding assays against [3H]-citalopram. This could be due to a variety of factors including low
transporter expression within the cell line and the radioligand being “sticky” through binding to
the membrane preps rather than the transporter. In addition, the concentration of the radioligand
used within the binding assays was chosen based on the recommendation of near the Kd value,
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which was a concentration higher than reported in the literature and potentially led to the issues
with the binding assays due to the candidate compounds not able to displace the radioligand. In
addition, the limited supply of the radioligands ([3H]-serotonin and [3H]-citalopram) led to
compromises in number of assays that could be with the focus taken on the substrate inhibition
assays and the competition binding assays rather than the total binding and release assay. In
addition, the positive control, the SSRI sertraline, used with the binding assays was old stock found
within the laboratory, which the age of the compound may have contributed to some of the erratic
results of the compound. Also, the release assay was completed using the inhibitor citalopram as
a control due to the lack of a releaser such as amphetamine.
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Chapter 5: Conclusions
This doctoral thesis is the accumulation of many years of work between the Surratt and Madura
laboratories, which were among the first groups merging computational chemistry with classical
pharmacology to target the MATs. One of the primary goals was to showcase how an academic
research environment can be used to efficiently identify candidate compounds through
computational methods, which is traditionally a costly endeavor of preclinical development. The
publication of the LeuBAT and dDAT crystal structures in 2013 provided structural templates
more closely aligned to the human SERT than the LeuT based SERT model used in the prior two
virtual screens by the laboratories. Thus, construction of SERT homology models based on these
templates began before shifting focus when the SERT crystal structures were eventually published
by the Gouaux lab in 2016. The virtual screen completed within this study targeted the S1 binding
site, which is now firmly believed to be the antidepressant binding site rather than the S2 site on
the LeuT proteins. The computational approach utilized the MOE software and set out to
thoroughly examine the scoring functions using a test set of known binders to identify the
parameters that will provide the best opportunity to identify novel inhibitors within a reasonable
amount of computational time to screen chemical libraries. The Maybridge chemical library as
part of ThermoFisher was a logical library to screen due to its recent curation of the HitDiscoverer
collection and the affordability of the compounds itself at under $100 per compound. An analytical
route was chosen to rank and filter the results of the virtual screen leading to a focus on the 10
compounds purchased from ThermoFisher. In all, only 9 compounds were able to be fulfilled for
this study. With a HEK-293 cell line stably expressing SERT that was generously donated by Dr.
Randy Blakely, assays were completed to assess binding, inhibition, and release potential of the
candidate compounds to SERT. While only compound 4 had comparable specific binding
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compared to the positive control sertraline in the total binding assay, compounds 1 and 4 were
determined to inhibit SERT with IC50s in the single µM range. None of the compounds were
shown to cause the release of serotonin. Computational modeling of compounds 1 and 4 revealed
that both adopted similar orientations within the S1 site, but also revealed that compound 4 forming
an ionic interaction with Asp98, which might be responsible for the increased potency. This study
successfully demonstrated that the computational approach is a valid direction to identify
inhibitors in a cost-effective manner and suitable for academic research laboratories.
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Appendix

Table A1. Second Validation of the Docking Protocol with the Structural Pharmacophore. After
the structural pharmacophore was placed on D98, the docking protocol was re-evaluated using the
24 compound test set using the Pearson, Spearman, and Kendall correlation tests. Each compound
is sorted by its experimental affinity (kcals) and displayed is the predicted affinity of the docking
simulation.
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Table A.2: Table of the DNA genes and the decoded proteins utilized by the PDSP during the
GPCR screen.
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PDSP GPCR Results for Compound 1

Table A.3: Results of the PDSP GPCR functional screen for candidate compound 1. Each
receptor listed while the average percent of activation is list.
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PDSP GPCR Results for Compound 2

Table A.4: Results of the PDSP GPCR functional screen for candidate compound 2. Each
receptor listed while the average percent of activation is list.
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PDSP GPCR Results for Compound 4

Table A.5: Results of the PDSP GPCR functional screen for candidate compound 4. Each
receptor listed while the average percent of activation is list.
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PDSP GPCR Results for Compound 5

Table A.6: Results of the PDSP GPCR functional screen for candidate compound 5. Each
receptor listed while the average percent of activation is list.
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PDSP GPCR Results for Compound 6

Table A.7: Results of the PDSP GPCR functional screen for candidate compound 5. Each
receptor listed while the average percent of activation is list.
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PDSP GPCR Results for Candidate 6

Table A.8: Results of the PDSP GPCR functional screen for candidate compound 6. Each
receptor listed while the average percent of activation is list.
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PDSP GPCR Results for Compound 7

Table A.9: Results of the PDSP GPCR functional screen for candidate compound 7. Each
receptor listed while the average percent of activation is list.
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PDSP GPCR Results for Compound 8

Table A.10: Results of the PDSP GPCR functional screen for candidate compound 8. Each
receptor listed while the average percent of activation is list.
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PDSP GPCR Results for Compound 9

Table A.11: Results of the PDSP GPCR functional screen for candidate compound 9. Each
receptor listed while the average percent of activation is list.
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Figure A.1: Competition of Sertraline for [3H]-Citalopram Binding to SERT. The affinity of
sertraline, compound 1, compound 4, compound 6, compound 8, and compound 10 (1pM-100mM)
for SERT was assessed by competition binding using the radioligand [3H]-citalopram. A
composite binding curve was constructed from individual curves. Composite affinity (IC50, Ki)
values were derived by GraphPad Prism non-linear regression analyses least squares fit. Each data
point represents the mean +/- (SD) of two to four independent experiments performed in duplicate.
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